



# FOGSI GCPR

SCREENING AND TREATMENT OF PREINVASIVE LESIONS OF CERVIX  
AND  
HPV VACCINATION



FOGSI Gynaecologic Oncology Committee

January, 2018





# FOGSI GCPR

SCREENING AND TREATMENT OF PREINVASIVE LESIONS OF CERVIX  
AND  
HPV VACCINATION



**FOGSI GCPR on Screening and Treatment of  
Preinvasive Lesions of Cervix & HPV vaccination**

<b>President In-charge</b>	: Dr. Rishma Pai
<b>Vice President In-charge</b>	: Dr. Ranjana Khanna
<b>Patrons</b>	: Dr. CN Purandare Dr. Alka Kriplani Dr. Usha Saraiya Dr. Kamal Buckshee
<b>Convenor</b>	: Dr. Neerja Bhatla, <i>Chairperson</i> <i>FOGSI Gynecologic Oncology Committee</i>
<b>Coordinator</b>	: Dr. Seema Singhal Dr. Shikha Shrivastava
<b>Co-Coordiators</b>	: Dr. Jyoti Meena, Dr Jayashree Natarajan

**National Experts :**

Dr. Abraham Peedicayil	Dr. Nikhil Purandare	Dr. Saritha Shamsunder
Dr. Alka Kriplani	Dr. Niranjan Chavan	Dr. Seema Singhal
Dr. Amita Maheshwari	Dr. Pakhee Agarwal	Dr. Shalini Rajaram
Dr. Bhagyalaxmi Nayak	Dr. Partha Basu	Dr. Shikha Shrivastava
Dr. Bharti Dhorepatil	Dr. R. Sankarnarayanan	Dr. Smita Joshi
Dr. Bindiya Gupta	Dr. Radha Bai Prabhu	Dr. Sunesh Kumar
Dr. Dipanwita Banerjee	Dr. Rama Joshi	Dr. Swaraj Batra
Dr. Gauri Gandhi	Dr. Ranjana Khanna	Dr. Uma Singh
Dr. Jyoti Meena	Dr. Rishma Pai	Dr. Usha Saraiya
Dr. Krishnendu Gupta	Dr. Ruchi Pathak	Dr. Vijay Zutshi
Dr. Mala Arora	Dr. Rupinder Sekhon	
Dr. Neerja Bhatla	Dr. Sarita Bhalerao	

**Management and Coordination:** Ms. Deepti Mathur, *Senior Specialist, Knowledge Management, PSI*  
Dr. Parul Saxena, *Assistant Manager, PSI*

# INTRODUCTION



**DR NEERJA BHATLA**

*Chairperson*

FOGSI Gynaecologic Oncology Committee

India is a land of diversity and this is reflected also in the varied practices followed for cervical screening. For years we have followed guidelines of various foreign societies, simultaneously lamenting the lack of uniformity of resources in our country. Also, each one of us works across different scenarios, sometimes in a tertiary hospital with state of the art facilities and sometimes in a camp setting. The FOGSI Gynaecologic Oncology Committee takes great pleasure in presenting GCPR for the Indian situation. The first step is to identify which situation you are working in – good resource or low resource – and accordingly to identify the options for screening, triage for confirmation of diagnosis and management. Recognising that the bulk of cervical cancer in India manifests after the age of 30 years, FOGSI recommends that screening should be started at 25 years for good resource and 30 years for low resource settings. FOGSI recognises that while HPV testing is the best method, all the screening tests, namely, HPV, cytology, co-testing with both HPV and cytology, and VIA, are all valid options. The critical steps are maintenance of quality control and follow up and treatment of screen detected lesions. Single visit approach is to be practiced wherever possible to minimise non-compliance and loss to follow up. The charts

show the screening algorithms for each type of screening method and management of various grades of CIN. All options have been evaluated and recommended based on global evidence and Indian data which have been extensively reviewed by the group of experts.

Primary prevention with HPV vaccine is strongly recommended. FOGSI endorses the WHO recommendation that the preferred age group is under 15 years, where two doses can be administered at an interval of 6 months. The charts also outline the recommendations for older girls and women and also for special situations. It is to be emphasised that screening must be continued in all vaccinated women too.

This work would not have been possible without the inspiration from our seniors and the hard work and commitment of the expert panel. I am grateful to each one of them for their untiring support and insights, guided by personal experience. I am also thankful to PSI for their partnership and support to bring this work to fruition. I am confident that you will find the FOGSI GCPR useful in your day-to-day practice and helpful in our common battle to eliminate cervical cancer.

January 17, 2018



# CONTENTS



<b>SECTION 1: SCREENING AND TREATMENT OF PREINVASIVE LESIONS OF CERVIX</b>	<b>1</b>
1. Introduction	3
2. Screening: Age and periodicity	9
3. Screening using available modalities	11
4. Newer modalities	29
5. Screening in immunocompromised women	31
6. Screening in pregnancy	33
7. Management of Cervical Intraepithelial Neiplasia (CIN)	35
References	45
<b>SECTION 2: HPV VACCINATION</b>	<b>55</b>
1. Introduction	57
2. Safety and Efficacy	59
3. Target population, Dosage schedule and duration of Protection	61
4. Special situations	63
5. Special populations	67
References	69



**1**  
SECTION



**Screening and  
Treatment of Preinvasive  
Lesions of Cervix**



# Introduction

## BACKGROUND

Cervical cancer is a major public health problem in India with an incidence of 1,22,844 cases and mortality of 67,477 cases every year.<sup>1,2,3</sup> Carcinoma cervix is the second most common gynecological malignancy amongst Indian women aged 25-44 years with an incidence of 3.5% after carcinoma breast (28.6%).<sup>3,4</sup> The age-standardized incidence rate for carcinoma cervix in Indian women is 22 per 100,000 women per year, which is the highest in South Asia, compared to 19.2 in Bangladesh and 13 in Sri Lanka. Cervical cancer mortality is 12.43/100,000 per year 1-3. Due to the lack of an organized cervical screening program, the disease burden is high in India.<sup>5</sup> There is an intense need to standardize the diagnosis and management of preinvasive disease of cervix.

India is a vast country with diversity in social, cultural and religious practices, and this leads to differences in clinical practice and access to medical care with respect to screening and prevention of cervical carcinoma. Screening and treatment facilities are not available uniformly in the country and there are areas with a shortage of gynecologists, pathologists, laboratories and colposcopists, thus limiting the establishment of an effective screening program. Therefore there is a need to develop Good Clinical Practice Recommendation (GCPR) that are evidence-based and applicable to all possible clinical situations. Every screening program needs to

incorporate adequate treatment and follow up of each screen-positive case. The emphasis of these Recommendation remains the same accurate detection followed by optimum management of preinvasive lesions of the cervix.

These GCPR are unique as they have taken into consideration the available resources, clinical conditions, population preferences and research evidence in the Indian context while formulating the management algorithms. The FOGSI GCPR were developed by a panel of experts from all over the country. The experts reviewed the research evidence and met to formulate the Recommendation. After brainstorming sessions, a draft was prepared which was once again critically reviewed by all contributors. After incorporating all the suggestions the final document was prepared.

## RESOURCE STRATIFICATION

FOGSI GCPR gives the option of using the modality that is available to the clinicians in any part of the country, and also provides the comprehensive overview of follow up and treatment if anything abnormal is detected. Various guidelines on screening and treatment of precursor lesions in all resource settings have been published by the World Health Organization (WHO, 2014)<sup>6</sup>, Ministry of Health

and Family Welfare (MOHFW), 2016.<sup>7</sup> and the American Society of Clinical Oncology (ASCO, 2016).<sup>8</sup> FOGSI GCPR stratifies the healthcare systems into two major categories: settings with good resources and settings with limited resources. On the basis of resources available and individual preferences, one can choose the screening and treatment modality. In good resource settings, there is no lack of facilities including trained doctors, laboratories and equipment. Limited resource settings may

lack adequate equipment, technology or staff to perform and interpret the results. The suggested modalities for screening and triage in each setting are shown in Table 1.

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force. The strength of Recommendation was given to each good clinical practice recommendation as per the criteria endorsed by USPSTF in Table 2.

**TABLE 1:** Resource stratification and suggested modalities for screening and management of precancerous lesions of cervix

Setting	Screening tools	Triage	Management options	Single visit approach strategy
Good Resource Settings	Primary HPV DNA test or Co-testing (HPV test + Cytology) or Cytology or VIA	Cytology ± Newer modalities,* HPV test, HPV Genotyping for 16/18, Colposcopy, VIA	LEEP, Conization, Cryotherapy, Thermocoagulation	See and Treat Approach
Limited resource Settings**	VIA	Colposcopy if available	Cryotherapy LEEP ± Conization, Thermocoagulation	Screen and Treat Or Screen, See and Treat Approach

\* Newer modalities (p16, ki 67 testing, mRNA testing, E6,E7 protein testing)

\*\* Affordable HPV test (if available), including self-sampling, can be used.

**TABLE 2:** Strength of recommendation<sup>9</sup>

Quality of Evidence	Definition
I	Evidence obtained from at least one properly designed randomized controlled trial
II-1	Evidence obtained from well-designed controlled trials without randomization
II-2	Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group
II-3	Evidence obtained from multiple time series with or without the intervention Dramatic results in uncontrolled experiments also could be regarded as this type of evidence
III	Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees
Based on the highest level of evidence found in the data, Recommendation are provided and graded according to the following categories:	
Level A	Recommendation are based on good and consistent scientific evidence
Level B	Recommendation are based on limited or inconsistent scientific evidence
Level C	Recommendation are based primarily on consensus and expert opinion

## SINGLE VISIT APPROACH

Successful implementation of cervical cancer prevention programs requires good linkages between screening and treatment. In the multiple visit approach there is a high incidence of loss to follow up and failure of compliance with recommended treatment. The single visit approach was initially tried in colposcopy clinics (See and Treat approach) but a similar strategy where Visual Inspection with Acetic Acid (VIA) and cryotherapy are performed in the same visit (Screen and Treat Approach) has been found to be effective, feasible and cost effective for resource constraint settings. Single round of screening in women > 35 years has led to 25% reduction in life time risk of cervical cancer.<sup>10,11</sup> The suggested criteria for Single visit approach are shown in Table 3.

**TABLE 3 :** Criteria for single visit approach

<b>See and Treat</b>	<b>Screen and Treat</b>
<i>In Colposcopy clinics</i>	<i>In Public Health Programs</i>
Patient referred with abnormal cytology report	VIA detects abnormal lesion
Colposcopy scoring indicates a high grade lesion	Criteria for ablation fulfilled
Simultaneous treatment done – excision or ablation	Treat immediately, with or without biopsy
Low probability of over-treatment because high specificity of cytology	Lower probability of over-treatment in high prevalence areas
Post-hoc analysis of biopsy report/excision specimen	Post-hoc analysis is possible if biopsy was taken

### See and Treat approach

In a study done to evaluate the over-treatment rate when choosing a See and Treat approach in patients with deviant cervical smear test results, 723 patients were analysed. High grade CIN was found in 70.3% of patients with LSIL showing that 29.7% of patients will be over-treated with a See and Treat approach. For patients with HSIL, the

rates of over-treatment were 6.7%.<sup>12</sup> Moreover See and Treat was more useful in women with ASC-H and HSIL cytology as immediate linkage to treatment led to better compliance and lesser chances of missing the lesions at biopsy.<sup>13</sup>

### Screen, See and Treat approach

This strategy was associated with 66% defaulter rates when patients were referred to other centers for colposcopy, but when colposcopy was done on the same site 97% women underwent the procedure and received optimum treatment. However a higher incidence of over-treatment was observed.<sup>14</sup>

WHO has recommended evidence-based guidelines for treatment of CIN<sup>2,3</sup> and Screen and Treat strategies to prevent cervical cancer. Depending on the availability of resources a strategy of Screen with an HPV test and Treat with cryotherapy or a strategy to Screen with VIA and treat with cryotherapy or LEEP is recommended. The same expert panel has suggested that a strategy to Screen with HPV and Treat with cryotherapy or LEEP is preferred over a strategy of Screen with cytology or HPV test followed by colposcopy and Treat with cryotherapy (Screen, See and Treat)<sup>15</sup>.


## HOW TO CHOOSE AN APPROPRIATE SCREENING MODALITY

The three main screening modalities are Human Papillomavirus (HPV) testing, cytology (Pap smear) and Visual Inspection by acetic Acid (VIA). FOGSI recommends the use of HPV testing as the best method for cervical cancer screening, alone or in combination with cytology. However, centers with an established cytology program with good quality indicators may continue to do the same. VIA is a test with sensitivity comparable to cytology and suitable for use in low resource settings. Wherever possible, colposcopy should be used to obtain a guided biopsy. However, in

its absence, the biopsy can be guided by VIA. In certain low resource settings, small low grade lesions may be considered for Screen and Treat approach without biopsy confirmation. Figure 1 depicts the algorithm to help clinician choose the

most appropriate screening modality applicable to their health care setting. Table 4 summarizes FOGSI Recommendation for screening in different resource situations. Each of these has been further discussed in detail below.

**FIGURE 1:** Algorithm to help clinicians select the most appropriate screening modality based on resources



Adapted from WHO<sup>6</sup> guidelines for Screening and treatment of precancerous lesions for cervical cancer prevention.

**TABLE 4:** Summary of FOGSI resource-based cervical cancer screening Recommendation

	Good Resource Settings	Limited Resource Settings
Modality	HPV testing <ul style="list-style-type: none"> <li>• Primary HPV testing</li> <li>• Co-testing (HPV &amp; Cytology)</li> </ul> Cytology Colposcopy and biopsy VIA	VIA Colposcopy ± Biopsy
Target age group (years)	25-65	30 – 65 (N.B.: In post-menopausal women, screening with VIA may not be as effective)
Age to start (years)	Cytology/Primary HPV testing at 25 Co-testing at 30	30
Frequency	Primary HPV testing or Co-testing – every five years Cytology – every three years	Every 5 years (at least 1-3 times in a lifetime)

	Good Resource Settings	Limited Resource Settings
Age to stop (years)	65 with consistent negative results in last 15 years - women with no prior screening should undergo tests once at 65 years and, if negative, they should exit screening.	
Follow up after treatment (Method and Interval)	HPV testing (preferred) or Cytology 12 months	VIA 12 months
Screening following abnormal reports $\geq$ CIN 2+, irrespective of method of treatment	20 years	
Screening in hysterectomized women	<ul style="list-style-type: none"> <li>• Following hysterectomy in which cervix was removed for benign causes : no need for screening, unless there is history of previous cervical intraepithelial neoplasia</li> <li>• Absence of cervix must be confirmed by clinical records or examination</li> <li>• If indications for hysterectomy unclear, screening may be performed at clinician's discretion</li> </ul>	
Follow up in women with CIN in hysterectomy HPE report	<ul style="list-style-type: none"> <li>• Need to be screened with HPV at 6 months and 18 months</li> </ul>	



# Screening: Age and periodicity

## 2

### AGE TO START SCREENING

In India, the burden of cervical cancer under the age of 30 years is very low and under 25 years is negligible. Women under the age of 25 should therefore not be screened regardless of the age of sexual initiation or other risk factors unless they present with symptoms.<sup>16</sup> Even in the West, the incidence of cervical cancer in women aged < 21 years has not changed with increased screening coverage over the last 4 decades.<sup>17</sup> Screening very young women is associated with relatively higher rates of unnecessary evaluation and treatment of lesions that would otherwise regress.<sup>18</sup>

#### Recommendation

- In health care settings with good resources, screening should begin from age 25 years. (Level A)
- In health care settings with limited resources, screening can be delayed till age 30 years. (Level B)

### SCREENING PERIODICITY

Women aged 30-65 years should preferably be screened with primary HPV testing or combined cytology and HPV testing (“co-testing”) every five years. If the quality of HPV testing is of

doubtful validity using non-standardized HPV testing methods, co-testing is to be preferred to primary HPV testing alone, till enough data accrues. In case HPV testing is not available, cytology alone/VIA is an acceptable modality and should be repeated every three years.<sup>19</sup> Liquid-based cytology does not improve the sensitivity over conventional cytology though it does decrease the rates of unsatisfactory smears and also allows the same sample to be used for other tests including HPV testing, gonorrhoea, chlamydia, etc. Annual screening has no advantage, rather leads to an increased number of unnecessary colposcopies and is not currently recommended for any category.<sup>20,21,22</sup>

In low resource situations, Ministry of Health and Family Welfare recommends five-yearly screening with VIA till the age of 65 years. It is expected that this group of women will receive screening at least one to three times in their lives. Hence screening with cytology every three years or HPV test every five years is optimal to achieve maximum benefits.<sup>23</sup>

#### Recommendation

- In health care settings with good resources, women aged 25-65 years should undergo cervical cancer screening preferably with primary HPV test/co-testing every five years or with cytology every three years. (Level A)

- In health care settings with limited resources, women aged 30-65 years should undergo cervical cancer screening with VIA every five years, at least one-three times in their lives. (Level B)

## AGE TO STOP

If screening is continued to age 90 years, the chance of preventing cervical cancer was only 1.6 cases and 0.5 deaths per 1000 women. Moreover it will lead to 58 extra false positives, 127 preventable colposcopies, 13 extra CIN cases undergoing treatment and adding life expectancy by only one year per 1000 women.<sup>24</sup> Therefore women over 65 years of age with previous adequate negative screening and no history of CIN2+ within the last 20 years need not be screened.<sup>24</sup> Adequate negative prior screening means three consecutive negative cytology results or 2 consecutive negative co-tests within the 10 years prior to ceasing of screening, with the last test having taken place within the last five years. In women who have undergone hysterectomy with a report of CIN2+

lesions, screening should be continued for 20 years from the age of surgery.

## Recommendation

- Regardless of resource situation, women should continue to be screened for cervical cancer till the age of 65 years. Thereafter screening can be discontinued in women with consistent negative results in the last 15 years. (Level A)
- In women who have undergone hysterectomy for benign reasons, screening is not advised, unless there is a history of previous cervical intraepithelial neoplasia. (Level A). Absence of a cervix must be confirmed by clinical records or examination. However if the indication for hysterectomy is not clear, screening may be performed at the clinician's discretion
- In women who have undergone any modality of treatment for CIN 2+, screening for 20 years following the time of treatment recommended. (Level A)

# Screening using available modalities

## 3

### HPV TEST AS PRIMARY SCREENING MODALITY

#### Primary HPV testing

HPV is the main causal factor for the development of cervical cancer. Eighteen HPV sub-types including HPV16 and HPV18 are known to be associated with invasive cancer.<sup>25</sup> HPV testing alone for primary screening is recommended in women aged 30 years and older, as a negative HPV test provides greater reassurance against CIN3+ in the subsequent five to seven years than cytology alone, and is nearly as reassuring as a negative co-test.

The cumulative incidence rates of CIN3 and cancer in HPV-negative women aged > 25 years was reported as 0.34% (95% CI, 0.10–0.65) and in cytology-negative women it was 0.78% (95% CI, 0.53–1.09).<sup>26</sup> Three year CIR of CIN3+ in women who were HPV negative and cytology negative was 0.30% (95% CI, 0.05–0.62). Although the primary hrHPV screening detected approximately 50% more CIN3+ as compared to cytology, it also resulted in a higher number of colposcopies.


Ronco *et al.*<sup>27</sup> analyzed follow up data from four published RCTs of hrHPV-based screening including the NTCC (Italy), ARTISTIC (United

Kingdom), Swede screen (Sweden), and POBASCAM (Netherlands) trials. There was no difference in cancer detection in the first 2.5 years, but after extended follow up, the incidence of invasive cervical cancer was significantly lower in women initially screened with hrHPV-based testing, compared to cytology alone test. (RR, 0.45; 95% CI, 0.25– 0.81).

The benefit of using HPV testing as a primary screening method is its high sensitivity and negative predictive value, and this allows safe prolongation of the screening intervals.<sup>28</sup> HPV testing is the recommended primary screening method in women aged ≥ 30 years. Recently, the Cobas test (Roche) which detects hrHPV, and genotypes HPV 16/18, has been approved for primary HPV testing in women aged >25 years.<sup>9</sup> HPV testing is a preferred method of co-testing in women >30 years or as primary screening at age >25 years, depending on the test used.<sup>29</sup> It is useful in triaging women with ASCUS cytology<sup>30</sup> and following treatment for CIN. It is more sensitive but less specific than cytology in post treatment follow up and this leads to earlier diagnosis of persistent or recurrent disease<sup>31</sup>.

It is hoped that in time the development of affordable, point-of-care HPV tests will permit the use of HPV testing in limited resource settings also.

**CHART 1:** Screening of women aged > 30 years with primary HPV testing



## Recommendation

*Presently, HPV testing is available only in good resource settings.*

- For women aged 30-64 years, primary HPV testing is an acceptable screening method. (Level A)
- Women with negative HPV test, should return to next screening after one years. (Level A)
- Women with positive HPV test should be triaged either with cytology, HPV genotyping or VIA, depending on availability. (Level B)
- When HPV positive women are triaged with cytology, a normal cytology report should be followed by a repeat HPV test at one year. If cytology report is  $\geq$  ASCUS colposcopy and directed biopsy should be advised. (Level A)
- When HPV positive women are triaged with HPV genotyping 16, 18, a positive result should be managed with colposcopy and directed biopsy, and further follow up should be done as per CIN management charts. If HPV genotyping is negative in an otherwise HPV positive woman then one can offer cytology. (Level B)

- When HPV positive women are triaged with VIA, a negative VIA should be followed by repeat HPV test at one year. On the other hand if VIA is positive, colposcopy and directed biopsy should be advised. (Level B)

Further follow up and management should be done as per FOGSI CIN management chart

## Choice of HPV test

HPV tests detect high-risk HPV types, either by amplification of a viral DNA fragment (with or without genotyping), or through mRNA identification.

HPV DNA tests identify the DNA of one or more oncogenic HPV types with direct genomic detection or by amplification of a viral DNA fragment using Polymerase Chain Reaction (PCR) to obtain copies, both conventionally and in real-time. HPV genotyping identifies specific viral types (usually HPV 16 and 18). The mRNA tests detect expression of HPV E6 and E7 oncoproteins.

The U.S. Food and Drug Administration (FDA) in 1997 approved Digene Hybrid Capture (HC) HPV DNA for triaging women with equivocal cytology report. In 2003 HC2 came as an adjunctive screen with cervical cytology for

**TABLE 5 :** HPV tests used for cervical cancer screening

Test	Technique	Name
DNA	Direct Genome detection	Hybrid Capture 2
		careHPV test
	Amplification	GP5+/GP6+ bio PCR-EIA
		Cervista HPV HR
		Cervista HPV 16/18
	Amplification and genotyping of HPV-16 and HPV-18	Cobas HPV test
		Xpert HPV
RNA	Amplification of E6/E7 proteins	Abbott Real time high risk HPV assay
		Papillo check
	Monoclonal antibodies	Aptima HPV assay
		PreTect HPV-Proofer HPV
		AVantage HPV E6 Test

women 30 years and older. HC2 has been the gold standard for cervical cancer screening until 2011-2012 when FDA approved Aptima, Cervista and CobasHPV assay.

HPV testing can not differentiate between persistent and transient infection, therefore it has 3%–4% lower specificity than cytology (at cutoff ASCUS+).<sup>32</sup> hrHPV detection methods comprise of HPV DNA assays and E6/E7 mRNA assays. Hybrid capture II and G5+/6+ are clinically validated prototype assay as they have shown better performance in lowering the incidence of CIN3+.

## CO-TESTING AS PRIMARY SCREENING MODALITY

For women aged 30-65 years, co-testing with combined cytology and HPV testing every five years is the preferred method of screening presently. Although there has been widespread endorsement of primary HPV testing,<sup>9</sup> FOGSI perceives the need for more Indian data on the validity of primary HPV testing before this is endorsed as the preferred method in India. The negative predictive value is high when both test results are negative and there is a very high level of reassurance that they will not be at risk for cervical cancer for a long time. Thus incorporation of HPV testing with cytology has the potential to reduce the incidence and mortality of cervical cancer in women aged 30 years and older.<sup>33,34,35</sup>

Co-testing leads to earlier diagnosis of CIN 3+ and Cancer.<sup>4</sup> Incorporating HPV with cytology helps in finding more AIS than cytology alone and negative co-test allows spacing of screening in every five years.<sup>27,37</sup> Co-testing has been successfully implemented in developed countries like The United States and recent data show a continued decline in cervical cancer rates.

Studies have also shown that incorporating HPV testing detects more AIS than cytology alone. The meta analysis of four large RCTs<sup>38,39</sup> namely

NTCC phase1, POBASCAM, Swede screen and ARTISTIC trial, compared co-testing with cytology screening alone in European women aged 30 to 64 years. The cumulative CIN3+ detection after two rounds of screening was similar between co-testing and cytology group.<sup>38,39,40</sup>


The patients with negative co-testing have a lower incidence of cervical cancer.<sup>41</sup> The 5-year cumulative incidence of CIN 3 or cancer was less than half the risk associated with negative cytology alone.<sup>41</sup> This is the basis of extending the screening interval from every three years to every five years with the use of co-testing.<sup>37</sup>

While HPV testing is more sensitive than cervical cytology testing, it is somewhat less specific. Co-testing in women younger than 30 years would lead to an increase in unnecessary work-up procedures without a corresponding decrease in cervical carcinoma incidence because of increased probability of clearance of infection by the immune system.<sup>42</sup>

Dillner and colleagues<sup>34</sup> using pooled data from European studies showed a greater reduction in CIN3+ disease in co-testing cohort than primary HPV screening cohort. Co-testing was more specific than primary HPV at six years follow up as CIN3+ disease was found in 24% fewer women in co-test negative cohort than negative primary HPV cohort. Similarly other studies have also confirmed that co-testing with Pap+HPV identified more cervical pre cancers and invasive cancers than the HPV or Pap test alone.<sup>43,44</sup> Moreover co-testing using highly specific HPV assay was clinically better and more cost effective as compared to primary HPV testing.<sup>45</sup>

The older version of United States Preventive Services Task Force (USPSTF)<sup>36</sup> organizations endorsed concurrent Pap and HPV testing (“co-testing”) for women age 30 and older in the cervical cancer screening guidelines<sup>28</sup>, but the latest guidelines recommend primary HPV screening as the preferred modality over co-testing. The women who test HPV-negative/Pap-negative have enough safety

**CHART 2 :** Screening with Co-testing (HPV test with cytology) in women aged > 30 years



against cervical cancer so that they can return for routine screening in five years. However, in India there is limited availability of HPV testing and often the tests used are not standardized. Hence it is preferable at the present time to recommend co-testing until sufficient Indian data accrues.

## Recommendation (Chart 2)

- For women aged 30-64 years, co-testing is the preferred screening method if resources are available (Level A)
- The women with negative cytology and HPV test should return to routine screening with co-testing at five years. (Level A)
- For women with positive cytology and negative HPV test, the follow up depends on the cytology test result:
  - a. If cytology is ASCUS or LSIL, repeat co-testing is advised at one year. (Level B)
  - b. Women with cytology  $\geq$  ASCUS or HPV test positive on repeat co-testing, should be managed by colposcopy and directed biopsy. (Level A)
  - c. Women with ASC-H or HSIL on cytology and HPV test negative, should be managed by colposcopy and directed biopsy. (Level A)
- The women with HPV test positive and cytology negative, should either go for repeat co-testing at one year or should go for HPV specific genotyping. (Level C):
  - a. Women who go for HPV genotyping, if the result is negative should be followed by repeat co-testing at one year and any abnormal test results should be managed as per FOGSI GCPR recommendation. (Level B)
  - b. If the HPV genotype result is positive, it should be managed by colposcopy and directed biopsy. (Level A)

## CYTOLOGY AS THE PRIMARY SCREENING MODALITY

Cervical cytology is the most commonly used screening test for detecting cervical preinvasive and invasive lesions of the cervix. Terminology for reporting cervical cytology was standardized by the Bethesda System in 1988 and was revised last in 2014.<sup>46</sup>

It is important to highlight that the results of cervical cytology cannot be used to make a definitive diagnosis or start treatment, except when it is HSIL. Rather, the results are used to guide further evaluation with colposcopy and or biopsy, and treatment decisions are based upon diagnostic results from such examination.

### Terminology for squamous cell abnormalities<sup>46</sup>

#### *Interpretation of cervical cytology reports*

A. Squamous cell abnormalities in the cytology report can be interpreted as Cervical Squamous Intraepithelial Lesions (CSIL) which are further stratified into:

- **Lowgrade Squamous Intraepithelial Lesion (LSIL):** LSIL in young women is a transient HPV infection and has relatively lesser risk of cancer progression. This is associated with probable histologic diagnosis of CIN 1
- **Highgrade Squamous Intraepithelial Lesion (HSIL):** This is associated with probable histologic diagnosis of CIN 2/3
- **Atypical squamous cells:**
  - ◆ **ASCUS**
  - ◆ **ASC-H:** LSIL cervical cytologic specimens that contain a few cells that are suspicious for, but not diagnostic of HSIL are reported as atypical squamous cells, cannot exclude a highgrade squamous intraepithelial lesion (ASC-H). Approximately 5 to 10% of ASC results are designated ASC-H

## Glandular cell abnormalities

Benign appearing endometrial cells are reported only in women  $\geq 45$  years.

- **Atypical Glandular Cells (AGC):** Endocervical, endometrial, or not otherwise specified is noted. Upon further evaluation, either highgrade squamous or glandular abnormalities are found in 10 to 39% of women with a finding of AGC on cytology
- **Atypical Glandular Cells, Favor Neoplasia (AGC-FN):** Endocervical or not otherwise specified is noted. This designation is for specimens that show features suggestive of but not sufficient for an interpretation of adenocarcinoma

- Endocervical Adenocarcinoma in Situ (AIS)
- Adenocarcinoma

### Summary of rationale for management protocols

#### Risk of malignancy in age group 30-64 years

The risk of progression of abnormality varies with each cytological abnormalities. (Table 6) Depending on the five year risk of progression to CIN lesion grade 3 or more, follow up protocols are decided. (Table 7)<sup>47,48,49</sup>

**Follow up protocols**<sup>50</sup> based on the five year risk of CIN lesion grade 3 or more severe, the recommended protocol is given in Table 7.

**TABLE 6:** Risk of progression with cytological abnormalities

Cervical cytology	Incidence		
	CIN 2+	CIN3+	Invasive
NILM	0.68%	0.26%	0.025%
<b>LSIL</b>			
Only cytology	16%	5.2%	6.1%
LSIL, HPV +	19%	6.1%	
LSIL HPV -	5.1%	2.0%	
<b>ASCUS</b>			
Only Cytology	6.9%	2.6%	0.18%
HPV +	18%	6.8%	0.41%
HPV -	1.1%	0.43%	
<b>ASC-H</b>			
Cytology alone	35%	18%	2.6%
HSIL	69%	47%	7.3%
Atypical glandular cells	13%	8.5%	2.7%
Squamous cell cancer	84%	84%	68%

**TABLE 7 :** Follow up protocols based on risk of progression

Risk of progression	Recommended modality
>5 %	Colposcopy
2 to 5 %	Repeat testing in 6 to 12 months
0.1 to 2 %	Repeat testing in three years
<0.1%	Repeat testing in five years (the same as routine screening)

## Management of ASCUS in women aged 30-64 years


The relative incidence of finding ASCUS in cervical cytology in this age group is approximately 2.8%.<sup>48</sup> The risk of having higher grade abnormalities in this age group varies depending upon HPV positivity as depicted in Table 7. The prevalence of HPV positivity with ASCUS cytology is 23-74%.<sup>51</sup> An ASCUS report on cytology can be triaged either with reflex HPV or repeat cytology or immediate colposcopy.

ASCUS/LSIL Triage Study (ALTS)<sup>52</sup> was a landmark randomized controlled trial that evaluated the strategies to manage ASCUS report. In this trial, 3488 women with ASCUS report were recruited to either immediate colposcopy, HPV triage, or repeat cytology at six months interval. In the repeat cytology group cytology was done every six months for two years and colposcopy was reserved for women with report of HSIL. The HPV triage group was found to have the highest sensitivity for detection of cumulative cases of CIN 3 (72.3%). Conversely the immediate colposcopy and conservative

management groups had similar sensitivity (54.6% and 55%). The rate of colposcopy referrals were lowest in the conservative management group (12%), followed by HPV triage (56%), and by definition, immediate colposcopy (100%). A single enrolment HPV test could detect 92.4% of the CIN grade 3 cases. Repeated cytology, would have required two visits to achieve similar performance sensitivity (95.4%) and would have referred 67.1% to colposcopy even at an ASCUS threshold. Therefore, in women with ASCUS cytology, for detecting CIN 3, HPV triage is as sensitive as immediate colposcopy, and at the same time, it also reduces colposcopy referrals to half. On the other hand, six monthly repeat cytology strategy, requires at least two follow up visits and more colposcopy examinations than HPV triage. However the main limitation of this trial is that it was conducted in 2001 and at that time ASCUS category also included ASC-H. Thus the background rate of HPV infection and CIN 3 was relatively higher.

Cost effectiveness of triage of ASCUS with reflex HPV test has been found as the most cost effective strategy as compared to

**CHART 3 :** Management of ASCUS in women aged 30-64 years



immediate colposcopy, repeat cytology, and two-visit HPV testing.<sup>53,54,55</sup> Furthermore, HPV genotyping would not result in a change in management from a positive HPV test, but would add cost. Conversely, there is a 15-33% risk of missing a significant abnormality if one relies on a single repeat smear, and also there is a need for multiple follow up visits, delay in histological diagnosis and also lack of protocols about optimum frequency of testing.<sup>56,57</sup> In women with persistent HPV infection but normal colposcopy, the risk of developing invasive disease is higher than those with transient infection.

The five-year risk of CIN3+ in women with single positive test and negative cytology was 4.5%, but it increased to 7.4%<sup>58</sup> in those with persistent HPV positive cases. Similarly, another study observed the five-year risk of CIN 3+ with a single HPV positive test and negative cytology as 2% and it increased to 8% in women with two positive results.<sup>59</sup> This explains the rationale behind doing co-testing in such situations at one year. Conversely the five-year risk of CIN3+ was similar in both HPV negative ASCUS (0.43%) and negative cytology regardless of HPV status (0.26%). However, the risk in those with negative cytology and negative HPV testing was minimal (0.08%).<sup>48,60</sup>

### Recommendation (Chart 3)

- Women aged 30-64 years with ASCUS cytology should be triaged preferably with HPV. (Level A)
- The women with ASCUS cytology and positive HPV test should be managed by colposcopy and directed biopsy. (Level A)
- The women with ASCUS cytology and negative HPV test should be followed with co-testing at 5 years. (Level B)
- In women with HPV positive ASCUS, normal colposcopy result should be followed by repeat co-testing at one year and any abnormal test results

should be managed as per FOGSI GCPR recommendation. (Level B)

- Women aged 30-64 years with ASCUS cytology can also be triaged with repeat cytology at one year if facilities for HPV are not available. In situations where the patient is noncompliant then depending on the availability one can either do colposcopy or VIA, followed by biopsy if suspicious areas are identified. (Level C)
- In women with ASCUS cytology report, triage with repeat cytology at one year. If repeat cytology is negative then patient should return to routine screening with cytology at three years. (Level B)
- In women with ASCUS cytology report, triage with repeat cytology at one year, If repeat cytology is ASCUS or LSIL, colposcopy and directed biopsy should be done and if that is normal, a cytology should be repeated after one year. The abnormal colposcopy results should be managed as per FOGSI GCPR chart. (Level B)
- The cytology report showing ASC-H or HSIL should be managed as per FOGSI GCPR

### Management of LSIL in women aged 30-64 years

Women aged 30-64 years when screened with cytology, 0.97% will have report as low grade squamous Intraepithelial lesions<sup>61</sup>. LSIL is associated with higher rates of HPV positivity. The risk of CIN 2+ and invasive disease with LSIL is shown in Table. The Kaiser Permanente study of almost 1,000,000 women ages 30 to 64 years, showed that women with LSIL who were HPV positive had a clinically significant increased risk of finding high grade disease compared with HPV negative women. (Table) The ALTS trial observed HPV positivity rates of 80% in women with LSIL cytology. Rate of decline of HPV positivity is only modest in women with LSIL cytology (88%


in 30-14 years and 72% in women aged 60-64 years) than with ASCUS (56% in women aged 30-34 years and 29% in women 60-64 years).<sup>52</sup>

Therefore majority of the guidelines do not recommend the use of HPV triage with LSIL cytology, contrary to ASCUS cytology even in women aged > 30 years. The ALTS trial was undertaken to compare the strategy of LSIL cytology in 1572 women. They were followed up either with immediate colposcopy or triage based on enrollment HPV DNA testing and liquid-based cytology at a colposcopy referral threshold of High grade Squamous Intraepithelial Lesion (HSIL), or conservative management based on repeat cytology at a referral threshold of HSIL. All arms included two years of semiannual follow up and colposcopy at exit. Loop electrosurgical excision procedure was offered to women with histologic diagnoses of Cervical Intraepithelial Neoplasia (CIN) grade 2 or 3 at any visit or persistent CIN grade 1 at exit. The main study end point was two-year cumulative diagnosis of

CIN grade 3. The two-year cumulative diagnosis of CIN grade 3 was approximately 15% in all study arms. The HPV triage arm was closed early because more than 80% of women were HPV positive, precluding efficient triage. The immediate colposcopy strategy yielded 55.9% sensitivity for cumulative cases of CIN grade 3 diagnosed over two years. A conservative management strategy of repeat cytology at the HSIL threshold referred 18.8% of women while detecting 48.4% of cumulative CIN grade 3. At lower cytology thresholds, sensitivity would improve but would ultimately yield unacceptably high referral rates. Therefore it was concluded that LSIL cytology is best managed by colposcopy initially, because there was no useful triage strategy identified. Management of these patients, after colposcopy to rule out immediately overt CIN grade 2 or 3, needs to be determined<sup>52</sup>.

A meta analysis was conducted to assess the difference in efficacy of immediate colposcopy and repeat cytology. The meta analysis revealed at

**CHART 4:** Management of LSIL in women aged 30-64 years



least double rate of CIN1 detection when women undergo colposcopy immediately as opposed to repeat cytology (21 vs. 8%, RR: 2.58, 1.69–3.94), suggesting that immediate colposcopy may increase the detection of insignificant lesions. The overall rate of CIN2 was significantly higher for the immediate colposcopy group at 18 months (6.5 vs. 3.2%, RR: 2.04, 1.52–2.73), although the differences became insignificant at 24 months of surveillance (7.6 vs. 5.4%, RR: 1.45, 0.87–2.40). The incidence of CIN2+ was significantly higher for the immediate colposcopy group at the first time point (before the exit examination at the time of completion), but became insignificant with time. Thus it was concluded that incidence of CIN2, CIN21, and CIN31 or worse at 24 months. The cumulative incidence of the above histological outcomes was higher for immediate colposcopy as opposed to cytology but the difference were not significant possibly due to smaller samples size (CIN2: 8.4 vs. 11.6%, RR: 1.72, 0.66–4.48; CIN21: 23.4 vs. 27.5%, RR: 1.43, 0.51–4.01, CIN31: 15 vs. 15.9%, RR: 1.24, 0.39–3.94) Immediate colposcopy significantly increased the detection of CIN31 as opposed to cytological surveillance (30.9 vs. 17%, RR: 1.80, 1.11–2.92, heterogeneity:  $p = 0.10$ ,

12.562%)<sup>61</sup>.


## Recommendation (Chart 4)

- Women aged 30-64 years with cytology report LSIL should preferably undergo colposcopy and biopsy. (Level A)
- HPV triaging is acceptable in women aged 30-64 years with cytology report of LSIL. (Level B)

## Management of ASCUS or LSIL cytology in women aged < 30 years

In this age group the incidence of cervical cancer is 1.4/100,000 women but the incidence of HPV infection is as high as 40.4%<sup>50</sup>. Therefore HPV testing is not of much importance in this age group. CIN 2 lesions regressed in 70% of younger women (mean age 20.4 years) For CIN 3, the estimated progression rate from CIN 3 to cancer in one year is as low as 0.5 percent. Apart from this the colposcopy and treatment may do more harms than benefit, therefore colposcopy should be done in this age group only if cytology results are persistent or severe.

**CHART 5:** Management of ASCUS / LSIL in women aged 25-29 years



## Recommendations (Chart 5)

- Cytology result showing ASCUS or LSIL in women aged 25-29 years HPV testing should not be done. (Level A)
- These patients should be followed preferably with repeat cytology at one year twice, or if patient is non-compliant and facilities are not available, then colposcopy or VIA is an acceptable modality. (Level C)
- If repeat cytology is Negative for intraepithelial lesions or malignancy can return to routine age specific screening. (Level B)
- If repeat cytology is ASCUS or higher colposcopy and directed biopsy should be done and if normal cytology should be repeated at one year. (Level B) If colposcopy is abnormal the patient should be managed as per FOGSI GCPR recommendations

### LSIL in women aged 25-29 years

These women have a higher prevalence of HPV but at the same time there is increased chances of spontaneous regression with low risk of

progressing into invasive disease. Therefore the management in this age group is based solely on the cytology results.<sup>62,63</sup>

### LSIL in postmenopausal age group


Post menopausal women with LSIL cytology should be triaged either with reflex HPV or repeat cytology at 6 and 12 months or colposcopy.

If HPV is positive, colposcopy is done but if HPV is negative then a repeat cytology should be done at 12 months. If two consecutive test reports are negative then the patient may return to routine screening. Similarly if triaged with repeat cytology at 6 and 12 months if repeat test shows a result of ASCUS or higher, colposcopy should be performed.<sup>64,65,66</sup>

### Management of women with ASC-H cytology (Atypical squamous cells cannot exclude high grade squamous Intraepithelial lesion on cervical cytology).

The probability of finding ASC-H in a cytology report is only 0.17%. The risk of invasive disease with this cytology is depicted in Table 7.<sup>48</sup> The rate of HPV positivity in women with ASC-H cytology

**CHART 6 :** Management of ASC-H, HSIL in women aged ≥ 30 years



**\* Eligibility for Ablative procedures:**

1. Lesion should be entirely visible and occupy not more than two quadrants of cervix
2. Entire lesion should be located on ectocervix without any vaginal and/or endocervical extension
3. Lesion can be adequately covered by largest cryotherapy probe available
4. There is no suspicion of invasive cancer
5. Screen and treat by cryotherapy is contraindicated in cases of postcoital or postmenopausal bleeding, obvious cervical growth, irregular surface or bleeding on touch

is as high as 67%. Therefore, HPV testing is not required because it does not affect management of the patient. These women should be evaluated by colposcopy with special attention given to adequate visualization of transformation zone and endocervical curettage. However, if the above conditions are not fulfilled, a diagnostic excisional procedure should be done. This protocol is applicable in younger women with ASC-H also.<sup>50,67</sup>

### Recommendation (Chart 6)

- All women with ASC-H cytology should be evaluated by colposcopy. (Level A)

### Evaluation of HSIL

The relative incidence of finding a cytology report as high grade squamous Intraepithelial lesion is approximately 0.21%.<sup>48</sup> These women are at substantial risk of developing high grade CIN and invasive disease, therefore they need further evaluation. There is no role of HPV triage in this group because of high incidence of HPV positivity (89-97%).<sup>68</sup> The strategy for managing these women is to do either colposcopy or immediate LEEP.<sup>30,50</sup> While doing colposcopy,

endocervical sampling is mandatory and if the colposcopy is unsatisfactory, except during pregnancy, a diagnostic excisional procedure should be the next step. A negative colposcopy implies that the colposcopic examination is adequate and the endocervical curettage is negative. Immediate cervical ablation is discouraged because ablative procedures do not provide a specimen for diagnostic evaluation.

### Recommendation (Chart 6 & 7)


- Women with cervical cytology report of HSIL should be advised to undergo colposcopy and directed biopsy. (Level A)

### Evaluation of atypical and glandular cells in cytology report Terminology<sup>69,70</sup>

**Atypical glandular cells:** The subcategories include:

- Endocervical, endometrial or Not Otherwise Specified (NOS)
- (The term atypical glandular cells of undetermined significance is no more existing now)

**CHART 7:** Management of ASC-H, HSIL in women aged < 30 years desirous of pregnancy




- Atypical glandular cells favor neoplasia is the term used for specimens showing features suggestive of, but not sufficient for, interpretation of adenocarcinoma
- Endocervical Adenocarcinoma in Situ (AIS)
- Adenocarcinoma


When glandular cell abnormalities are present, it should be noted whether there are changes favoring neoplasia. The relative incidence of typical glandular cells on cervical cytology is approximately 0.1-2.1%.<sup>71</sup> These cells are associated with pre-malignant or malignant disease in 30% instances in women older than 40 years.<sup>72</sup>

Even with atypical glandular cells the majority of lesions are squamous and not glandular. The presence of atypical glandular cells on cytology is a significant marker for the presence of pre-malignant disease and risk is known to increase with age.<sup>73</sup> Incidence of endometrial carcinoma was 12.7%, ovarian carcinoma 1.4%, and cervical adenocarcinoma was 0.9% in women more than 50 years with atypical glandular cells in cytology report. On the other hand, women 40-49 years with atypical glandular cells showed malignancy in only 2.8% cases and only 2% women < 40 years showed malignant changes.<sup>72</sup> Thus, it is mandatory to assess these women for both cervical as well as endometrial malignancy.


**CHART 8:** Management of abnormal glandular cells: Atypical Endometrial Cells



**CHART 9:** Management of abnormal glandular cells: AGC-NOS, Atypical Endocervical Cells



AGC-NOS: Atypical Glandular Cells-Not Otherwise Specified



\*Age > 35 yrs, high risk factors, e.g., obesity, chronic anovulation  
 AGC-FN - Atypical Glandular Cells Favouring Neoplasia; AIS - Adenocarcinoma in Situ

All women with any of the above mentioned AGC category, except AGC-endometrial, should be evaluated with colposcopy and directed cervical biopsy along with endocervical sampling. Endometrial sampling should be done for women > 35 years' age and also younger women if there is a high risk of developing endometrial malignancy. HPV testing is not required. Despite comprehensive evaluation, if a woman has negative findings then, possibility of other primary including ovarian, fallopian tube should be considered. A systematic review with 7000 women having a cytology report of atypical glandular cells, found that 6.4% had ovarian or fallopian tube carcinoma and 6.9% had cancers of sites other than the cervix, endometrium, ovaries, or fallopian tube.<sup>74</sup> These women should then be recommended a transvaginal ultrasound. Women with an adnexal mass are further evaluated for ovarian or tubal cancer.

### Recommendation (Chart 8, 9, 10)

- Women with cytology report of atypical glandular cells should be evaluated with colposcopy and directed biopsy along with endo cervical and endometrial sampling. (Level A)

### VIA AS PRIMARY SCREENING MODALITY

Visual inspection of the cervix with acetic acid is promising as a screening tool for low-resource settings because it is economical and provides immediate results. ASCO and WHO both recommend visual inspection with acetic acid for basic settings i.e. developing and under developed countries which lack the necessary resources of an organized cytology or HPV-based screening programme.<sup>6,8</sup> When VIA-based screening is initiated as population based screening it is important to ensure quality control and validated training and evaluation procedures.

In a study by Sankarnarayan *et al*, a single round of VIA screening by trained nurses led to increased detection of preinvasive disease and reduced mortality (incidence hazard ratio 0.75 [95% CI 0.55–0.95] and mortality hazard ratio 0.65 [0.47–0.89]).<sup>75</sup>

Poli UR *et al*, published a seven years' experience using VIA in a community-based program in rural Andhra Pradesh, with a test positivity rates of 10.75% and prevalence of CIN2+ lesions as 1.05%. The rates of biopsy proven High grade

Squamous Intraepithelial Lesions (HSILs) was 0.48% and Lowgrade Squamous Intraepithelial Lesions (LSILs) was 0.28%.<sup>76</sup>

Another study by Saleh HS *et al*, VIA had a higher sensitivity of 90% versus 50% with Pap smear. However, specificity of VIA was low at 37% compared to 93.5% with cytology.<sup>77</sup>


In a recent meta analysis of 32 studies the pooled estimates for VIA sensitivity and specificity were 0.69 (95% CI 0.54-0.81) and 0.87 (95% CI 0.79-0.92), respectively.<sup>78</sup> A recent review by Adsul *et al* of 20 studies including a total of 313,553 women at 12 different sites across India has been published.<sup>79</sup> They have reported that in 10 studies at cut off of CIN 2+, sensitivity for VIA ranged from 16.6% to 82.6%, and specificity 82.1% to 96.8%. At CIN 3+, the sensitivity ranged from 7.7% to 67.9%, and specificity from 87.4% to 96.7%. They concluded that to facilitate-community based implementation of cervical cancer screening programs in India, there needs to be standardization of training to maintain competency of test providers; collaborations with community-based organizations for increased participation and

use of 'screen and treat' method to reduce loss in follow up.<sup>75</sup> VIA screening was associated with 31% reduction in cervical cancer mortality (RR = 0.69; 95% CI = 0.54 to 0.88; P = .003) and a better compliance in screened population than controls (86.3% versus 72.3%).<sup>80</sup>

WHO in a recent guidance has advocated that the lower age limit of cervical screening should not be under 30 years in LMIC VIA permits a single-visit approach providing Low Middle-income Countries (LMICs) in view of immediate test results and screen and treat approach.<sup>6</sup> In a modelling study for ascertaining the best screening strategy in developing countries, screening women once in their lifetime using VIA, at 35 years of age, reduced the lifetime risk of cancer by approximately 25 to 36%. The relative risk further reduced by an extra 40% with two rounds of screenings (at 35 and 40 years of age).<sup>76,77</sup>

To conclude, VIA is a feasible method to initiate mass screening in resource-poor settings which lack an organized screening program. Once VIA-based population screening has been implemented, efforts should also be made to initiate HPV testing, development and

**CHART 11 :** Screening with VIA



strengthening of infrastructure for diagnosis and treatment of preinvasive and invasive cancer.

### **Recommendation for VIA as a screening tool (Chart 11)**

- VIA can be used as a screening tool between 30-65 years. (level A)
- In limited-resource settings VIA should be done at least one to three times in a lifetime. (Level B)
- Screening by VIA should not be continued beyond 50 years, especially in menopausal women as transformation zone recedes into the endocervical canal and prevents it from being fully visible. (Level A)

### **Recommendation for VIA as a triage tool**

- In basic settings, visual assessment for treatment may be used after positive HPV DNA testing results. In cases of abnormal or positive triage results, treatment should be offered. When facility for colposcopy is available, it is preferable to do it before treatment. (Level B)
- If VIA was used as primary screening, women with abnormal results should receive treatment. (Level C)
- Women with negative triage results should receive follow up in 12 months. (Level B)



# Newer modalities

Infection with HPV leads to integration of viral DNA into the host DNA activating the proto-oncogenes to oncogenes, or deactivation of tumor suppressor genes; with consequent enhancing the rate of cell proliferation and Cervical Intraepithelial Neoplasia (CIN).<sup>81</sup>

In young sexually active women, 90% of HPV infections are transient and only persistent infection predisposes to cervical neoplasia. HPV-DNA testing is a highly sensitive test but cannot differentiate between transient and persistent infections.

The new generation of screening tests have evolved to identify markers that can discriminate between the transient and the persistent infections, which if left untreated, may progress to precancer and cancer. These markers are promising as they increase the PPV and specificity of the test and at the same time also reduce colposcopy referrals and unnecessary interventions.

## P16 AND Ki 67

The biomarker p16<sup>ink4a</sup>, a cyclin dependent kinase inhibitor is present at very low levels in normal cells, while it is over-expressed in pre-cancer and cancer. Ki-67 is a nuclear protein that is expressed in proliferating cells and a higher Ki-67 index has been correlated with poor histopathological grades of disease.<sup>82</sup> For p16 immunostaining Gustinucci *et al*, showed sensitivity and specificity of 91% and 64% for CIN2+ respectively in

ASCUS smears (n=213) and 77% and 64% for LSIL smears (n=186) respectively.<sup>82</sup> The sensitivity and specificity for p16/Ki-67 has been variably reported between 64% to 98% and 43% to 81% across several studies for diagnosis of CIN 2+ disease in low grade smears and this difference is due to variation in sample size and interpretation of results.<sup>83,84,85</sup>

Wang *Retal* showed that significantly high number of p16-positive cases of CIN-1 progressed as compared to p16-negative cases (27% versus 7%) and p16 protein staining had a high negative predictive value of 93% for progression to CIN II-III.<sup>86</sup>

In a study by Da Costa *et al*, ROC curves showed significant cutoff points of 0.396 and 0.026 for p16<sup>ink4a</sup> and Ki-67 ratios, respectively, as predictors of progression.

In a meta analysis of five studies, higher agreement for a CIN2+ and CIN3+ diagnosis with H&E morphology in conjunction with p16<sup>ink4a</sup> was observed compared with H&E morphology alone.<sup>87</sup>

The LAST guidelines concluded that p16 can be used to confirm a diagnosis of a high grade lesion in CIN-2/CIN1-2 on H/E morphology. p16 positive “CIN 2” will be labelled as “HSIL” while if p16 negative will be labelled “LSIL”. p16 staining will decide further treatment and Follow up in CIN 2 lesions and can be used to distinguish potential high grade lesion from a benign mimic.<sup>88</sup>

In a prospective analysis of the NTCC randomized controlled trial for HPV positive women, 8.8% [95% CI 5.8–11.8] p16 positive women had CIN2 or worse lesions compared to 3.7% [1.9–5.4] p16-negative women. Surveillance showed more CIN3 or worse was detected in more p16-positive women (4.4% [2.3–6.6]) than in p16-negative women (1.3% [0.2–2.3]; RR 3.90 [95% CI 1.57–9.68]).<sup>89</sup>

## DNA METHYLATION

Changes in DNA methylation cause defective gene expression, genetic instability through faulty condensation of chromosomes, and silencing of mobile DNAs such as jumping genes (transposons) and viruses. Methylation can be measured as a simple reflex in HPV-positive cases using Quantitative Methylation Specific PCR (qMSP).<sup>90</sup>

Methylation studies have been done on several genes of human genome namely MAL, CADM1, PAX-1, SOX-1 etc. A combination of CADM1 and MAL in hrHPV+ women from a screening population showed a sensitivity of 68% (95% CI 50–81%) and a specificity of 75% (95% CI 70–80%) for CIN 2+ disease. At another cut-off, the sensitivity of CADM1/MAL was 84% (95% CI 72–93%), the specificity was 52% (95% CI 48–57%), and the Positive Predictive Value (PPV) was 25% (95% CI 17–32%), with an AUC of 0.72.<sup>91</sup>

In a self-sampling study, DNA methylation testing for MAL and miR-124 was comparable with cytology as a triage tool in HPV positive women on self-collected specimens. The sensitivity for CIN2+ was 70.5% (95% CI 66.1–75.0%) and 70.8% (95% CI 66.1–75.4%) for methylation and cytology triage, respectively, while the PPV was significantly lower (31.7%, 95% CI 26.3–37.1%,  $p < 0.001$ ) for DNA methylation triage than for cytology triage (50.3%, 95% CI 42.3–58.4%).<sup>92</sup>

PAX1, SOX1 and POU4F3 have been used in studies in Asian women showing promising results. The sensitivity of PAX1 was 64% and for SOX1 was 71%, while the specificity was 91 and

77%, respectively, and the AUC was 0.77 and 0.83, respectively. The sensitivity and specificity of POU4F3 test taking CIN3+ cutoff is 74%, and 89%, respectively with an AUC of 0.86.<sup>93,94</sup>

## E6 AND E7 MRNA

In a study in HR HPV-positive women, E6/E7 mRNA positivity rate was 68.29% in women tested once and 69.56% in women tested twice in high grade lesions. The positivity rate was 89.28 to 84% in women tested once and varied from 77.77 to 70% when tested twice in women with lowgrade lesions.<sup>95</sup> In a comparative study on HR HPV E6/E7 mRNA and HR-HPV DNA in cervical cancer screening, HR-HPV E6/E7 mRNA test showed a higher specificity than HPV DNA tests for high grade lesions (61.4%, 54.3%, 55.7%, respectively,  $P < 0.05$ ) and also a higher positive predictive value (75.9%, 74.8%, 74.6% respectively) with the largest area of ROC curve and the best diagnostic value.<sup>96</sup>

In another study, the sensitivity of HPV E6/E7 mRNA expression was lower than HPV DNA positive test, the HPV E6/E7 mRNA assay showed significantly higher specificity than the HPV DNA assay (88.6% vs. 48.1%) in normal cytology samples.<sup>97</sup>

A large study on 396 samples demonstrated equal sensitivity for APTIMA E6E7 (AHPV) and hybrid capture 2 for diagnosis of invasive cancer. The sensitivity of AHPV and HC2 were 95.2% and 94.9% respectively with an agreement of 97.2% ( $\kappa$  0.7; 95%CI: 0.54–0.87).<sup>98</sup>

## HPV SELF-SAMPLING

Across various studies the acceptability of HPV self-sampling is high, due to its convenience, less discomfort and anxiety, ease of procedure and more convenience.<sup>99,100</sup>

The sensitivity of self-collected samples are variable across literature, between 60 to 90%, with moderate to good agreement.<sup>101,102,103,104,105</sup>

# Screening in immunocompromised women

## 5

Infection with HIV increases a woman's lifetime risk of developing cervical pre-malignant and malignant lesions, approximately 10% HIV positive women develop CIN2+ each year compared to 1–2% among HIV negative women.<sup>106</sup> In a meta analysis by Gary *et al* the prevalence of invasive cervical cancer was 4% and CIN2+ lesions was 8.5% among HIV positive women.<sup>107</sup> In a cross-sectional Indian study<sup>106</sup>, 1,128 HIV-infected women underwent VIA, VILI, cytology, HPV testing, and colposcopy. Regarding diagnostic performance of various modalities in HIV-infected population cytology was found to have a higher specificity than VIA and HPV testing but lower sensitivity than HPV testing. Sequential combinations of HPV testing and VIA; HPV testing and VIA; improved the specificity with minimal reduction in sensitivity.<sup>107,108</sup> VIA is a practical and useful screening test for HIV-infected women. The consideration for

prolonging the screening interval from 3 to 5 years for HIV-infected screen-negative women, is applicable to HIV-negative women in current practice.<sup>109</sup>

### FOGSI Recommendation

- Screening of HIV-positive women should start in the first year of diagnosis irrespective of age. (Level A)
- In order to enhance the coverage ART services should be integrated with cervical screening program. (Level B)
- In good-resource settings screening should be continued as per age Recommendation every three years upto 65 years. (Level A)
- In limited resource settings VIA should be done every three years upto 50 years. (Level B)



# Screening in pregnancy

The available evidence is insufficient to currently recommend the guidelines for pregnant or postpartum women and therefore, the practice points are based on expert consensus.

## Recommendation

- Pregnant women should undergo Speculum examination at first visit.
- If normal defer screening till postpartum period (six weeks). (Level B)
- If speculum examination is suggestive of abnormality, follow routine screening protocols. (Level B)



# Management of Cervical Intraepithelial Neoplasia (CIN)

## 7

In women who have been diagnosed with CIN on biopsy which may or may not be colposcopy guided, further management is guided by the preceding cytology and HPV report if available. This is important in the case of low grade CIN (CIN1) where the preceding cytology report can indicate the future CIN3+ risk. A preceding lowgrade cytology (ASCUS-LSIL/HPV+) has a five year risk of 3.8% versus 15% with preceding high grade cytology.<sup>30</sup>

Thus, in chart 12, Follow up with preceding low grade cytology is Follow up at one and two years, whereas with high grade smear more intensive Follow up – cytology at six months or even a diagnostic excision procedure is justified due to the discrepancy in cytology and histology reports. At any time during Follow up if testing is positive, a repeat colposcopy and biopsy is recommended and subsequent management as per the histopathology report. CIN 1 is thought to be the histologic manifestation of HPV infection. CIN 1 is also associated with non-oncogenic HPV types, and among the oncogenic ones, HPV-16 is less common than in CIN 3.<sup>110</sup> The natural history of CIN 1 is similar to ASCUS/HPV + and LSIL in the presence of normal colposcopy and biopsy (see table with pap smear and risk of CIN), suggesting similar follow up and management.<sup>111</sup>

Thus, treatment for CIN 1 preceded by lesser abnormalities is only warranted when it persists


for two years. Treatment can be in the form of ablative procedure if the criteria for ablation are fulfilled, or else excisional procedure is done.

CIN 1 preceded by high grade smear abnormalities can be kept on intensive follow up (due to the higher risk of CIN 3) if colposcopy is adequate and complete and there is no endocervical involvement. In case of a converse situation, diagnostic excision is done. If high grade smear abnormality persists for 12 months and no lesion is seen on colposcopy also diagnostic excision is warranted.

### Recommendation (Chart 12)

- Women diagnosed with CIN 1 on histology and preceded by lowgrade pap smear should be advised to continue with follow up under supervision. (Level A)
- In women with CIN 1 persisting for two years appropriate treatment should be advised. (Level A)
- Both ablation and excision are appropriate modalities for treatment. (Level B)
- Women with CIN 1 histology preceded by high grade smear abnormalities should be advised an intense follow up or immediate treatment depending on their compliance and desire. If high grade smear abnormality

**CHART 12:** Management of women with CIN 1 on histology



persists for 12 months and no lesion is seen on colposcopy a diagnostic excision is warranted. (Level B)

Regression rates are high, especially in younger women, and progression to CIN 2+ is uncommon.<sup>112</sup>

### Management of CIN in younger women (Chart 13)

Differences are-HPV is not part of Follow up. CIN 1 is a transient or stable HPV infection with minimal cancer risk, thus, treatment is not recommended in the first instance. HPV testing does not form part of follow up in women less than 30 years.

If CIN 1 is preceded by lesser abnormalities persists for one year then repeat colposcopy is done. If high grade abnormality persists for 1 year, diagnostic excision is done. This is based on the evidence from ASCCP that five year CIN3+ risk is 16-28% after ASC-H and HSIL in CIN1 but five year cancer risk is virtually nil. However, women with discrepancy in cytology and biopsy reports at the end of one year are subject to diagnostic excision to rule out underlying high grade disease.


### Recommendation (Chart 12 & 13)

- There is no role of HPV testing during follow up and treatment (Level A)
- If high grade abnormality persists for one year, treatment is acceptable (Level B)


### Cervical Intraepithelial Neoplasia (CIN) 2,3

As per WHO, 1-2% women are diagnosed to have CIN 2+ every year.<sup>6</sup> Up to 50% of CIN 2+ can regress over time. Thus, treatment is recommended if CIN2+ persists for two years. For CIN3+ treatment is recommended, as risk of progression is high enough (approximately 30-50%). Thus, women with a diagnosis of CIN3 are harboring the immediate precursor to invasive cancer and should not be observed, irrespective of age or concern about future fertility.

**CHART 13:** Management of women aged < 30 years with CIN 1 on histology desirous of pregnancy



**CHART 14:** Management of women with CIN 2,3 on histology



Where CIN 2 or 3 is not individually specified, management algorithm followed is as per chart 14. With high grade CIN, if colposcopy is adequate, both excision and ablation are adequate modalities of treatment.<sup>113</sup> However, excision is preferred for large lesions or lesions

not fully accessible for ablation. Diagnostic excisional procedure is recommended for recurrent CIN, if colposcopy is inadequate or if there is endocervical involvement, and ablation is unacceptable in these situations. Keeping CIN2/3 on follow up without treatment is not

acceptable as the primary therapy, neither is immediate hysterectomy for the same.

If the margins of a diagnostic excision are positive, cytology and ECC can be repeated after six months. This is preferable to the alternative of doing a repeat diagnostic excision, which is acceptable in individual cases. If a repeat excision is not technically feasible, hysterectomy is acceptable as well.

### Recommendation (Chart 14)

- With high grade CIN, if colposcopy is adequate, both excision and ablation are adequate modalities of treatment. (Level A)
- Excision is recommended if recurrent CIN, endocervical involvement or colposcopy is inadequate. (Level A)
- Follow up of CIN2/3 without treatment is unacceptable. (Level B)
- Immediate hysterectomy for CIN2/3 is unacceptable. (Level B)
- For positive margins after excision, cytology and ECC can be repeated after 6 months. (Level A)


- Hysterectomy as an alternative to repeat excision is feasible. (Level C)


In the context of young women, the aim is to treat women with high risk of developing invasive disease. Those who are not at high risk are observed and kept on follow up as treatment can have adverse consequences on future pregnancy. The aim is also to protect them from harms of over-treatment.<sup>114</sup>

As per chart 15, where CIN 2/3 is diagnosed (not individually specified), observation and follow up at six months and one year with cytology and colposcopy is an acceptable alternative to treatment, provided colposcopy is adequate. After two consecutive negative cytology results, an additional co-test at one year and three years is recommended. If either is abnormal, colposcopy and biopsy is performed and managed accordingly.

If CIN2 is specified, triage biomarkers may be done if available. Observation is preferred to treatment, unless triage biomarkers are positive. Treatment is an acceptable alternative if biomarkers are negative. During observation,

**CHART 15 :** Management of women with CIN 2,3 on histology and desirous of pregnancy





if the cytology becomes high grade or the colposcopic appearance of the lesion worsens at one year, repeat biopsy is recommended.<sup>114,115</sup>

If CIN3 is specified and colposcopy is inadequate, treatment (excisional procedure) is recommended. In CIN2 with positive biomarkers, or if CIN 2,3 persists during Follow up at six months and one year, treatment is recommended.

**Recommendation (Chart 15)**

- Observation without treatment for unspecified CIN 2/3 is acceptable provided colposcopy is adequate (Level A)
- If CIN2/3 persists during follow up at six month and one year, treatment is recommended (Level A)
- Observation is preferred to treatment if CIN2 is specified (Level A)
- Treatment is preferred to observation if CIN3 is specified or colposcopy is inadequate (Level A)
- Excision is preferred to ablation (Level B)

CIN in pregnancy-treatment for CIN during pregnancy is deferred unless invasive cancer is suspected. Patient is kept on Follow up

with colposcopy and cytology not more frequently than every 12 weeks. Repeat biopsy is recommended only if invasive cancer is suspected. Post-partum evaluation is deferred for six weeks postpartum.<sup>114</sup>

**Recommendation (Chart 16)**

- Diagnostic excision is advisable only if invasive cancer is suspected (Level A)
- Defer post-partum evaluation to six weeks (Level A)

**Organization of Outreach Community Camp for Cervical Cancer Screening**

In India there is poor access to screening and treatment services. The following barriers are identified for access to screening services:

- Lack of knowledge about cervical cancer
- No perceived need by women hence no apparent reason for screening
- Geographic and economic inaccessibility of services
- Discomfort during internal examination
- Lack of support from families and communities

- Stigma: Fear of getting screened positive
- Lack of knowledge about availability of treatment options among the population
- Preventive health still of primitive importance/value
- Female issues still a neglected component of the society
- Mismatch between the demand and the supply

Cancer of the cervix can be prevented by population based screening, which aims to detect the disease at a Precancerous stage when it is amenable to simple treatment and cure. Outreach camps can be helpful in overcoming the above mentioned barriers. The main purpose of organizing cervical cancer screening camps in outreach settings is to increase access to quality screening services for women of lower socio-economic category, living in hard to reach areas and to offer immediate treatment if required, thus reducing, the loss to follow up. Conducting outreach camps among groups of women helps to create awareness, moreover women get motivated by seeing others getting screened and feel relaxed.

For a successful execution of outreach community camps the following strategies can be planned -

**Site Selection Criteria:** An initial visit should be done to the selected site to ensure that the following criteria are fulfilled:

- Approachable to the community

- Clean
- Adequate running water supply/backup
- Functional toilet
- Well ventilated and airy
- Well lighted
- Electricity/Backup
- Room for processing of instruments—cleaning and availability of High-Level Disinfectants (HLD)
- Screening room with space of at least two examination tables
- Room/Space for counseling (to maintain privacy)
- Space/room for registration
- Waiting area with sitting arrangement for clients
- Sitting arrangement for accompanying person

**Human Resource:** In successful execution of outreach camps, the role of following are crucial -

### *Demand Generation*

- Community field workers – They are the main interface with the community who can mobilize the clients. Urban Social Health Activist (USHA), Accredited Social Health Activist (ASHA), Anganwadi Workers (AWW) or Non-government Organization

## **DO'S AND DON'TS FOR PLANNING OF CAMP**

Do's –	Don'ts –
<ul style="list-style-type: none"> <li>• Plan the camp well in advance.</li> <li>• Assign roles and responsibilities clearly.</li> <li>• Convey the VIA positive result to the client in a non-threatening and empathetic way.</li> <li>• Direct and Follow up with the VIA positive client needing services at higher centres.</li> <li>• Motivate clients to go back in the community and encourage others also, for screening.</li> <li>• Ensure correct data is captured on the formats.</li> </ul>	<ul style="list-style-type: none"> <li>• Don't overload the camp with clients. In order to assure quality of service delivery one doctor can screen up to 50 clients in a day</li> </ul>

(NGO) workers of the selected site can support for demand generation and spreading information about the proposed camp among community

- Local heads in the community like Member of Legislative Council (MLC), religious leaders, or any other influential person may be of help in orienting the community

### **Service Provision**

- Trained doctor – for providing screening services
- Paramedical staff – for documentation work, counseling, supporting doctor during screening and ensuring follow up of VIA screened positive women
- Support staff – for cleaning/sterilization of equipment and managing group during camp

**Strategy for Demand Generation:** Women may not always be motivated to attend screening just because a new service is being provided. Carefully designed, targeted messages and strategies can be used to encourage women to take advantage of new services. Cervical cancer prevention services typically focus on women who are older (aged 30 to 59 years) and in need of other health services. Women's participation in screening can be improved by seeking out eligible women when they are reached for the health services, to attend to other problems. They can be provided other health check-ups like Hb, BP monitoring, blood sugar screening and nutritional counseling etc. Simultaneously with cervical cancer screening if feasible. Information brochures, leaflets, pamphlets, flyers, posters and banners can be used as awareness generation and propagation tools. These screening camps can also be organized for school/college staff, widows homes, handicraft workers, physically challenged women, women inmates in prison and workplace settings etc.

### **Management of clients during the camp**

- Assign roles and responsibilities and prepare a flow chart for women's movement during a screening camp
- Ensure better services for the clients on the camp day
- Organizing team must ensure its smooth functioning
- Provision of logistics for clients, sitting arrangements and drinking water
- Provision of logistics for sitting arrangements, food/snacks for the staff
- Separate designated areas for registration and counseling must be ensured
- Confidentiality of the screening results and other details are to be ensured

### **Counseling and follow up**

Counseling is an important component of service delivery. It satisfies women's information needs, reduces their anxiety and fear, and explores possible barriers to treatment, follow up. Following counseling related procedures should be followed as appropriate:

- Individual or group pre-screening counseling
- Counseling about screening results
- Individual counseling for women who need further care
- Pre/post treatment counseling for women treated with cryotherapy

## **DO'S AND DON'TS FOR COUNSELING**

### **Dos:**

- Make eye contact, listen attentively and take note of her body language (posture, facial expression, eye contact)

- Try to understand her feelings and point of view
- Use open-ended questions to invite more than “yes” or “no” answers
- Be empathetic: place yourself in the woman’s situation
- Use simple language and terms that the woman understands
- Answer her questions truthfully and allow enough time for the session
- To cross check ask the woman whether she is pregnant. If she is pregnant, ask her the age of gestation and explain to her accordingly
- After completing the pelvic examination, ask the woman if she is more comfortable discussing the results while lying on or sitting on the examination table
- Inform the women about VIA test findings
- Give detailed information about the treatment option
- Describe the benefits and effectiveness of cryotherapy
- Explain how the cryotherapy procedure is done and the potential side effects, also ensure that the woman understands
- Encourage the woman to ask questions and discuss her condition
- it is better to take consent for treatment along with screening consent, avoid two separate consents). Give the woman some time to decide if she has doubts, invite her to return later to inform you of what she (and possibly her family) has decided
- If you noted something for which you wish to refer her to a higher level for further examination or tests: Explain why,

where and when she must go, and whom to see

- Stress the importance of keeping this appointment
- Invite her to return if she has any questions or concerns about this appointment, and respond or find answers from someone who knows

### Don'ts:

- Appear to be distracted (looking at your watch, answering the phone)
- Use of harsh tone of voice, or act impatient
- Allow interruptions during the visit
- Interrupt the woman
- Be critical, judgmental or rude
- Overwhelm the woman with too much detail or irrelevant information
- Use medical words the woman does not understand
- Insensitively share the results without asking readiness of the client to hear the results
- Force a decision regarding treatment rather ask consent of the client for treatment
- Let the client leave without understanding the treatment options she has in her hands
- Be in a rush and not let the client ask questions she may have in her mind

**Ensuring Quality Services:** Good quality of services must be ensured through training of service providers on standard protocols. A monitoring checklist is given in the table below which will help in assessing the logistic arrangements, record filling and maintenance and infection prevention practices during the outreach community camp.

Sl. No	Monitoring Checklist
<b>A</b>	<b>Instruments &amp; materials required for VIA &amp; Cryotherapy</b>
1.	Drum-autoclaved (with speculum, sponge-holding forceps, steel bowl, green towel)
2.	Drum-autoclaved containing sterile cotton balls
3.	Acetic acid
4.	Container for preparing acetic acid solution
5.	Steel bowl
6.	Distilled water
7.	Measuring cylinder, syringe-5ml
8.	Sodium hypochlorite
9.	70% ethanol spray
10.	Normal saline
11.	Cusco speculum
12.	Sponge holder
13.	Mackintosh
14.	Mouth mask
15.	Gloves
16.	Towel
17.	Dustbins 3
18.	Disposable bags
19.	Gloves boxes 3, plastic gloves (if required)
20.	Boiler with plug
21.	Writing pad/board with clip for holding the forms
22.	Address cards, prescription pad
23.	Table/trolley
24.	Table fan
25.	Trolley, green towel
26.	Cryo machine with probe and Filled N2O Cylinder (optional)
27.	Extension board (for boiling instruments)
28.	Torch - 2, extra cells(LED torch preferably with four batteries)
29.	Register for keeping log
30.	Gynaec examination table, stool, writing table, chairs, hand sanitizer/Soap etc
<b>B</b>	<b>Record filling and maintenance</b>
31.	Consent forms to be signed by the beneficiaries
32.	Client Record Sheet

Sl. No	Monitoring Checklist
33.	Report Card/Follow up instructions card.
34.	Storage of client records properly done
<b>C</b>	<b>Infection prevention</b>
35.	Autoclaved instruments
36.	Hand hygiene practices followed by all staff
37.	Mackintosh placed on the examination table
38.	Gloves are changed after examining every patient
39.	Aprons are worn by the provider
40.	Hand rub/hand sanitizer available and used
41.	Mouth masks are used during Procedure
42.	Examination table cleaned in-between screening of clients Bleaching solution prepared in adequate amount and used instruments dipped in it for 10 minutes.

# References



1. Nanda kumar A, Ramnath T, Chaturvedi M. The magnitude of cancer cervix in India. *Indian J Med Res.* 2009;130(3):219-21.
2. Singh A, Kujur A. Changing trends in genital cancer. *Int J Reprod Contracept Obstet Gynecol* 2017;6:850-5.
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>, accessed on day/month/year.
4. National Centre for Disease Informatics and Research, National Cancer Registry Programme, ICMR. Time trends in cancer incidence rates, 1982-2010. Bangalore, India: NCDIR-NCRP (ICMR); 2013.
5. ICO Information Centre on HPV and cancer. Human Papillomavirus and Related Diseases in India (Summary Report 2014-08-22); 2014.
6. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization; 2013. WHO Guidelines Approved by the Guidelines Review Committee.
7. National guideline for cervical cancer screening programme. Department of health.
8. Jeronimo J, Castle PE, Temin S, Denny L, Gupta V *et al.* Secondary prevention of cervical cancer : ASCO resource stratified clinical practice guideline. *Journal Global Oncology.* DOI: 10.1200/JGO.2016.006577.
9. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, *et al.* American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *J Low Genit Tract Dis.* 2012; 16(3):175–204.
10. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC. Cost effectiveness of cervical-cancerscreening in five developing countries. *N Engl Med.* 2005;353 (20):2158–68.

11. Vet JNI, Kooijman JL, Henderson FC, *et al.* Single-visit approach of cervical cancer screening: See and Treat in Indonesia. *British Journal of Cancer*. 2012;107(5):772-777. doi:10.1038/bjc.2012.334.
12. Nooij LS, Kagie MJ. 'See and treat' approach for high grade squamous intraepithelial cervical lesions. *Eur J Gynaecol Oncol*. 2016;37(1):22-5.
13. Guducu N, Sidar G, Bassullu N, Turkmen I, Dunder I. Three-step approach versus see-and-treat approach in patients with cytological abnormalities. *Int J Clin Exp Med*. 2013; 6(5): 372–376.
14. Megevand E, Wybrand Van Wyk, Knight B, Bloch B. Can cervical cancer be prevented by a see, screen, and treat program? A pilot study. *Am J Obstet Gynecol* 1996;174:923-8.
15. Santesso N, *et al.*, World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2–3 and screen-and-treat strategies to prevent cervical cancer. *Int J Gynecol Obstet* 2015, <http://dx.doi.org/10.1016/j.ijgo.2015.07.038>.
16. Castle PE, Carreon JD. Practice improvement in cervical screening and management: symposium on management of cervical abnormalities in adolescents and young women. *J Low Genit Tract Dis* 2010;14:238Y40.
17. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *BMJ* 2009;339:b2968.
18. Moscicki AB, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. *J Low Genit Tract Dis* 2010;14:73Y80.
19. Kulasingam S, Havrilesky L, Ghebre R, Myers E. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2011. AHRQ Publication No.11-05157-EF-1.
20. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. *Arch Intern Med* 2008; 168:1881-9.
21. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. *Br J Cancer* 2004; 91:530-6.
22. Kim JJ, Wright TC, Goldie SJ. Cost effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. *J Natl Cancer Inst* 2005; 97:888-95.
23. Goldie SJ, Kim JJ, Wright TC. Cost effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. *Obstet Gynecol* 2004;103:619-31.
24. Kulasingam S, Havrilesky L, Ghebre R, Myers E. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2011. AHRQ Publication No.11-05157-EF-1.
25. Munoz N, Bosch FX, de Sanjose S, *et al.* human papillomavirus types associated with cervical cancer. *N Engl J Med*. 2003; 348:518.
26. Apple, T. Derion, T.L. Wright The ATHENA human papillomavirus study: design, methods, and baselineresults. *Am J Obstet Gynecol*. 2012; 206: 46e1-11.

27. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, *et al.* Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow up of four European randomized controlled trials. *Lancet* 2014; 383: 524–32.
28. Dillner J, Rebolj M, Birembaut P, *et al.* Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. *BMJ* 2008; 337: a1754.
29. W K *et al.* Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance *J Low Genit Tract Dis* 2015. 19(2); 91-96.
30. ASCCP Guidelines, *J Low Genit Tract Dis*, 2013; ACOG, 2016.
31. Kocken M *et al.* HPV testing versus cytology in predicting post-treatment disease in women treated for high grade cervical disease: a systematic review and meta analysis. *Gynecol Oncol* 2012; 125(2):500-7.
32. Arbyn M, Ronco G, Anttila A *et al.* Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. *Vaccine* 2012;30(5):88-99.
33. Ronco G, Giorgi-Rossi P, Carozzi F *et al.* Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. *Lancet Oncol* 2010; 11: 249-57.
34. Dillner J, Rebolj M, Birembaut P, *et al.* Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. *BMJ* 2008; 337: a1754.
35. Sankaranarayanan R, Nene BM, Shastri SS, *et al.* HPV screening for cervical cancer in rural India. *N Engl J Med* 2009; 360: 1385–94.
36. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012; 156 (12):880–91.
37. Saslow D, Solomon D, Lawson HW, *et al.* American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin* 2012; 62: 147-72.
38. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F *et al.* New Technologies for cervical cancer working group. Human papillomavirus testing and liquid based cytology: results at recruitment from new technologies for cervical cancer randomized controlled trial. *J Natl Cancer Inst.* 2006; 98: 765-74.
39. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgrén K *et al.* Human papillomavirus and Papanicolaou tests to screen for cervical cancer. *N Engl J Med.* 2007; 357: 1589-97.
40. Bulkman NW, Berkhof J, Rozendaal L, Van Kemenade FJ, Boeke AJ, Bulk S *et al.* Human papillomavirus DNA testing for detection of cervical intraepithelial neoplasia grade 3 and cancer: five-year follow up of a randomized controlled implementation trial. *Lancet.* 2007; 370: 1764-72.
41. Katki HA, Kinney WK, Fetterman B, *et al.* Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *Lancet Oncol* 2011; 12: 663-72.
42. Committee on Practice Bulletins—Gynecology ACOG Practice Bulletin

- Number 131: Screening for cervical cancer. *Obstet. Gynecol.* 2012; 120:1222–38.
43. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. *Cancer Cytopathol.* 2015; 123(5):282-88.
  44. Zhou H, Mody RR, Luna E, *et al.* Clinical performance of the food and drug administration-approved high-risk HPV test for the detection of high grade cervicovaginal lesions. *Cancer Cytopathol.* 2016;124:317-23.
  45. Felix JC, Lacey MJ, Miller JD, Lenhart M, Spitzer GM, Kulkarni R. The clinical and economic benefit of co-testing versus primary HPV testing for cervical cancer screening: A modeling analysis. *J Womens Health.* 2016;25(6):606-16.
  46. Waxman AG, Chelmow D, Darragh TM, *et al.* Revised terminology for cervical histopathology and its implications for management of high grade squamous intraepithelial lesions of the cervix. *Obstet Gynecol* 2012; 120:1465.
  47. Katki HA, Schiffman M, Castle PE, *et al.* Five year risk of CIN 3+ to guide the management of women aged 21 to 24 years. *J Low Genit Tract Dis* 2013; 17:S64.
  48. Katki HA, Schiffman M, Castle PE, *et al.* Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. *J Low Genit Tract Dis* 2013; 17:S28.
  49. Katki HA, Schiffman M, Castle PE, *et al.* Five year risks of CIN 2+ and CIN 3+ among women with HPV positive and HPV negative LSIL Pap results. *J Low Genit Tract Dis* 2013; 17:S43.
  50. Massad LS, Einstein MH, Huh WK, *et al.* 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *J Low Genit Tract Dis* 2013; 17:S1.
  51. O'Connor NR, Kumar P. Conservative management of end stage renal disease without dialysis: a systematic review. *J Palliat Med* 2012; 15:228.
  52. ASCUS LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. *Am J Obstet Gynecol* 2003; 188:1383.
  53. Arbyn M, Roelens J, Simoens C, *et al.* Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. *Cochrane Database Syst Rev* 2013; : CD008054.
  54. Kim JJ, Wright TC, Goldie SJ. Cost effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. *JAMA* 2002; 287:2382.
  55. Kulasingam SL, Kim JJ, Lawrence WF, *et al.* Cost effectiveness analysis based on the atypical squamous cells of undetermined significance/low grade squamous intraepithelial lesion Triage Study (ALTS). *J Natl Cancer Inst* 2006; 98:92.
  56. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic Human Papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *Lancet Oncol.* 2011; 12:880–890. [PubMed: 21865084].

57. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. *Obstet Gynecol.* 2007; 109:1325–1331. [PubMed: 17540804].
58. Katki HA, Schiffman M, Castle PE, *et al.* Five year risks of CIN 3+ and cervical cancer among women who test Pap negative but are HPV positive. *J Low Genit Tract Dis* 2013; 17:S56.
59. Kjær SK, Frederiksen K, Munk C, Iftner T. Long term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. *J Natl Cancer Inst* 2010; 102:1478.
60. 27. Committee on Practice Bulletins-Gynecology. Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. *Obstet Gynecol* 2016; 128:e111.
61. Kyrgiou M, Kalliala I, mitra A, Ng KYB, Raglan O, Fotopoulou C, Hirsch PM, Paraskeva E, Arbyn M. Immediate referral to colposcopy versus cytological surveillance for lowgrade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta analysis of the literature. *Int. J. Cancer* 2017; 140: 216–223.
62. Moscicki AB, Hills N, Shiboski S, *et al.* Risks for incident human papillomavirus infection and lowgrade squamous intraepithelial lesion development in young females. *JAMA* 2001; 285:2995.
63. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia grade 2. *Obstet Gynecol* 2009; 113:18.
64. Peyton CL, Gravitt PE, Hunt WC, *et al.* Determinants of genital human papillomavirus detection in a US population. *J Infect Dis* 2001; 183:1554.
65. Sherman ME, Schiffman M, Cox JT, Atypical Squamous Cells of Undetermined Significance/Low Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low Grade Squamous Intraepithelial Lesion Triage Study (ALTS). *J Natl Cancer Inst* 2002; 94:102.
66. Evans MF, Adamson CS, Papillo JL, *et al.* Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age.
67. Castle PE, Fetterman B, Thomas Cox J, *et al.* The age specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. *Obstet Gynecol* 2010; 116:76.
68. Katki HA, Schiffman M, Castle PE, *et al.* Five year risks of CIN 3+ and cervical cancer among women with HPV positive and HPV negative high grade Pap results. *J Low Genit Tract Dis* 2013; 17:S50.
69. Broder S. From the National Institutes of Health. *JAMA* 1992; 267:1892.
70. Solomon D, Davey D, Kurman R, *et al.* The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA* 2002; 287:2114.
71. Marques JP, Costa LB, Pinto AP, *et al.* Atypical glandular cells and cervical cancer: systematic review. *Rev Assoc Med Bras* (1992) 2011; 57:234.

72. Zhao C, Florea A, Onisko A, Austin RM. Histologic Follow up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. *Gynecol Oncol* 2009; 114:383.
73. Zhao C, Austin RM, Pan J, *et al.* Clinical significance of atypical glandular cells in conventional pap smears in a large, high risk U.S. west coast minority population. *Acta Cytol* 2009; 53:153.
74. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. *Obstet Gynecol* 2006; 107:701.
75. R. Sankaranarayanan, P.O. Esmey, R. Rajkumar, R. Muwonge, R. Swaminathan, S. Santhakumari, *et al.* Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster randomized trial. *Lancet* 2007; 370:398-06.
76. Poli UR, Bidinger PD, Gowrishankar S. Visual Inspection with Acetic Acid (VIA) Screening Program: seven Years Experience in Early Detection of Cervical Cancer and Pre-Cancers in Rural South India. *IJCM* 2015;40(3):203-7.
77. Saleh HS, ElHameid AA, Mowafy HE, Sherif HE, Abdelsalam WA. Visual Inspection of the Cervix with (Acetic Acid or Lugol's Iodine) for Cervical Cancer Screening. *Gynecol Obstet (Sunnyvale)* 2016;6: 111. doi:10.4172/2161-0932.S4:111.
78. Mustafa RA, Santesso N, Khatib R, Mustafa AA, Wiercioch W, Kehar R, *et al.* Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. *Int J Gynaecol Obstet.* 2016;132(3):259-65.
79. Adsul P, Manjunath N, Srinivas V, Arun A, Madhivanan P. Implementing community-based cervical cancer screening programs using visual inspection with acetic acid in India: A systematic review. *Cancer Epidemiol.* 2017;49:161-74.
80. Shastri SS, Mitra I, Mishra GA, Gupta S, Dikshit R, Singh S, Badwe RA. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. *J Natl Cancer Inst.* 2014;106(3):dju009.
81. Walboomers JM, Jacobs MV, Manos MM, *et al.* Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999;189:12-9.
82. Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S *et al.* Role of p16<sup>ink4a</sup> cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. *Acta Cytol.* 2012;56:506-14.
83. Schmidt D, Bergeron C, Denton KJ, Ridder R. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. *Cancer Cytopathol.* 2011; 119(3):158-66.
84. Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. *BJOG.* 2015;122(1):64-70.
85. Wentzensen N, Schwartz L, Zuna RE, *et al.* Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. *Clin Cancer Res.* 2012; 18(15): 4154-4162.

86. Wang R, Li X, Qian M, Niu J, You Z. The natural history of cervical intraepithelial neoplasia I and the clinical significance of p16<sup>ink4a</sup> protein as a marker of progression in cervical intraepithelial neoplasia I. *Zhonghua Fu Chan Ke Za Zhi*. 2015;50(3):210-5.
87. Reuschenbach M, Wentzensen N, Dijkstra MG, von Knebel Doeberitz M, Arbyn M. p16<sup>ink4a</sup> immunohistochemistry in cervical biopsy specimens: A systematic review and meta analysis of the interobserver agreement. *Am J Clin Pathol*. 2014;142:767-72.
88. Darragh TM, Colgan T, Cox JT, Heller DS, Henry MR, Luff RD, *et al*. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus Recommendation from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. *J Low Genit Tract Dis*. 2012; 16:205-42.
89. Carozzi F1, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G; NTCC working group. Risk of high grade cervical intraepithelial neoplasia during follow up in HPV-positive women according to baseline p16<sup>ink4a</sup> results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. *Lancet Oncol*. 2013;14(2):168-76.
90. Laird PW: Principles and challenges of genome-wide DNA methylation analysis. *Nat Rev Genet* 2010;11:191-203.
91. Hesselink AT, Heideman DAM, Steenbergen RDM, Coupe VMH, Overmeer RM, Rijkaart D, Berkhof J, Meijer CJLM, Snijders PJF: Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. *Clin Cancer Res* 2011;17:2459-2465.
92. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, Bekkers RL, Steenbergen RD, Massuger LF, Melchers WJ, Bulten J, Overbeek LI, Berkhof J, Snijders PJ, Meijer CJ: Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROTECT-3): a randomised controlled non-inferiority trial. *Lancet Oncol* 2014;15:315-322.
93. Lai HC, Ou YC, Chen TC, Huang HJ, Cheng YM, Chen CH, Chu TY, Hsu ST, Liu CB, Hung YC, Wen KC, Yu MH, Wang K: PAX1/SOX1 DNA methylation and cervical neoplasia detection: a Taiwanese Gynecologic Oncology Group (TGOG) study. *Cancer Med* 2014;3:1062-1074.
94. Chang CC, Ou YC, Wang KL, Chang TC, Cheng YM, Chen CH, Chu TY, Hsu ST, Liou WS, Chang YY, Wu HH, Chen TH, Lai HC: Triage of atypical glandular cell by SOX1 and POU4F3 methylation: a Taiwanese Gynecologic Oncology Group (TGOG) study. *PLoS One* 2015;10:e0128705.
95. Fontecha N, Basaras M, Hernández S, Andía D, Cisterna R. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker. *BMC Cancer*. 2016 5;16(1):852.
96. Zhao X<sup>1</sup>, Cui Y, Jiang S, Meng Y, Liu A, Wei L, *et al*. Comparative study of HR HPV E6/E7 mRNA and HR-HPV DNA in cervical cancer screening. *Zhonghua Yi Xue Za Zhi*. 2014;94(43):3432-5.
97. Wang HY, Lee D, Park S, Kim G, Kim S, Han L, *et al*. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening

- of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China. *Asian Pac J Cancer Prev.* 2015;16(17):7633-40.
98. Basu P, Banerjee D<sup>1</sup>, Mittal S<sup>1</sup>, Dutta S<sup>1</sup>, Ghosh I<sup>1</sup>, Chowdhury N<sup>1</sup>, Abraham P<sup>2</sup>, Chandna P<sup>3</sup>, Ratnam S. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers. *J Med Virol.* 2016 Jul;88(7):1271-8.
  99. Anhang R, Nelson JA, Telerant R, Chiasson MA, Wright TC., Jr Acceptability of self-collection of specimens for HPV DNA testing in an urban population. *J Womens Health (Larchmt)* 2005;14(8):721-8.
  100. Kahn JA, Bernstein DI, Rosenthal SL, Huang B, Kollar LM, Colyer JL, *et al.* Acceptability of human papillomavirus self testing in female adolescents. *Sex Transm Infect.* 2005;81(5):408-14.
  101. Karwalajtys T, Howard M, Sellors JW, Kaczorowski J. Vaginal self sampling versus physician cervical sampling for HPV among younger and older women. *Sex Transm Infect.* 2006;82(4):337-9.
  102. Gök M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, *et al.* HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. *BMJ.* 2010;340:c1040. Erratum in: *BMJ* 2016;353:i2823.
  103. Snijders PJ, Verhoef VM, Arbyn M, *et al.* High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. *Int J Cancer.* 2013; 132(10):2223-2236.
  104. Petignat P, Faltin DL, Bruchim I, *et al.* Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta analysis. *Gynecol Oncol* 2007; 105: 530-5.
  105. Gök M, Heideman DA, van Kemenade FJ, *et al.* HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. *BMJ* 2010; 340: c1040.
  106. Joshi S *et al.* Screening of cervical neoplasia in HIV-infected women in India. *AIDS,* 2013, 27(4):607- 615.
  107. Gary M. Clifford *et al* Carcinogenicity of human papillomavirus types in HIV-positive women: A meta analysis from HPV infection to cervical cancer. *Clin Infect Dis* 2017.
  108. Sahasrabuddhe VV *et al.* Comparison of visual inspection with acetic acid and cervical cytology to detect high grade cervical neoplasia among HIV-infected women in India. *International Journal of Cancer,* 2012, 130(1):234-240.
  109. Adler DH, Wallace M, Bennie T, *et al.* Cervical dysplasia and high-risk HPV infections among HIV-infected and HIV-uninfected adolescent females in South Africa. *Infect Dis Obstet Gynecol.* 2014.
  110. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, *et al.* Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. *J Natl Cancer Inst* 2003;95:1336Y43.

111. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. *Am J Obstet Gynecol* 2003;188:1406Y12.
112. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, *et al.* Regression of lowgrade squamous intraepithelial lesions in young women. *Lancet*. 2004;364:1678Y83.
113. Cochrane review- Martin-Hirsch PP, Paraskevaidis E, Bryant A, *et al.* Surgery for cervical intraepithelial neoplasia. *Cochrane Database Syst Rev* 2010; :CD001318.
114. WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ 2014.
115. WHO GUIDELINES- Use of cryotherapy for cervical intraepithelial neoplasia 2011.



# 2

SECTION

## HPV Vaccination





# Introduction

Persistent infection with oncogenic types of human papillomavirus has been shown to be the necessary cause of cervical cancer.<sup>1</sup>

About 6.6% of Indian women in the general population have HPV infection at any given time.<sup>2</sup> Most of the time, HPV infection does not cause any manifestations and is self-limited. It has been observed that approximately 70% of all newly acquired HPV infections are cleared within one year, and approximately another 20% in the next one year. In some women infection persists and may cause cervical cancer and other manifestations including oropharyngeal cancers, anogenital cancers and genital warts.

Human Papillomavirus is a non-enveloped, small, double stranded DNA of the family papilloma viridae. The viral genome consists of 7200-8000 base pairs and the early fragments of the genome regulates DNA replication (E1, E2), transcription (E2) and cell transformation (E5, E6, E7) and late fragments (L1 & L2) encode structural proteins of the virion. Purified L1 protein form empty shells resembling a virus, called Virus-Like Particles (VLPs).

HPV are largely non-lytic and restricted to the epithelium. Antibodies will be formed in serum against many different viral proteins. The most characterized antibodies formed are those directed against conformational epitopes of the

L1 capsid and detectable antibodies are not found in all infected persons. In a study by Carter *et al*, 54%-69% of women who were found to be infected with HPV 6, 16, or 18 infections had type-specific antibody.<sup>3</sup>

More than 100 types of HPV have been recognized on the basis of DNA sequence showing genomic differences.<sup>2</sup> Infection with HPV types 1 and 2 cause warts in some individuals while HPV-5 may cause lifelong infection without any clinical manifestation. Infection with HPV types 6 and 11 can cause laryngeal papillomatosis and genital warts. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are considered to be carcinogenic.<sup>4</sup> HPV 16 and 18 are high-risk types and account for over 75% of invasive cervical cancers in South Asia.<sup>5</sup>

In India approximately 80% of cervical cancer and 63% of high grade cervical lesions are linked with infection due to HPV 16 and 18.<sup>6</sup> Age and sexual activity are the major influencing factors for HPV transmission. About 75% of sexually active individuals harbor at least one HPV type.<sup>7</sup> Risk of HPV infection can be reduced by an HPV type-specific targeted vaccine. Abstinence or lifetime mutual monogamy is helpful in preventing genital HPV infection. There is limited evidence to suggest the protective role of condoms and male circumcision against HPV infection.<sup>8</sup>

## CHARACTERISTICS OF HPV VACCINE

	Bivalent Cervarix	Quadrivalent Gardasil	Nonavalent Gardasil 9
Manufacturers	Glaxo Smith Kline	Merck	Merck
HPV types in vaccine	16,18	6,11,16,18	6,11,16,18,31,33,45,52,58
Adjuvant in vaccine	AS04:500ug aluminium hydroxide 50ug 3-O-desacyl-4'-monophosphoryl lipid A	AAHS:225ug amorphous aluminium hydroxyphosphate sulfate	AAHS:500ug amorphous aluminium hydroxyphosphate sulfate

## TYPES OF HPV VACCINES

In India two HPV vaccines are available presently which are globally licensed: quadrivalent vaccine (Gardasil<sup>TM</sup>, Merck Inc.) and bivalent (Cervarix<sup>TM</sup>, Glaxo Smith Kline, Ltd.)<sup>9</sup>. The third,

a nonavalent vaccine, was US FDA approved in 2014, but is not yet available in India. Both vaccine comprise type-specific major capsid protein L1 synthesised by recombinant DNA technology. The vaccines do not lead to any infection in the individual.

# Safety and Efficacy

## SAFETY

Extensive data on the safety of HPV vaccines are available from clinical trials and population programs. Globally, more than 270 million doses have been administered with no serious adverse event linked to the HPV vaccine and with an excellent safety profile. Adverse events reported after HPV vaccine administration were generally mild in intensity and like those expected after any vaccination. These included vaccination site pain, tenderness, swelling, fever, headache, myalgia and gastrointestinal symptoms.<sup>10,11</sup> The safety of HPV vaccines is monitored by the WHO Global advisory committee for vaccine safety (GACVS) which regularly reviews the evidence related to their safety. GACVS in 2016 stated that decreased use of safe and effective vaccines based on weak evidence can lead to harm and the available evidence does not raise any concern related to the safe use of HPV vaccines.<sup>12</sup>

## CONTRAINDICATIONS

- Allergy to yeast and yeast products
- Allergy to previous dose of HPV vaccine (irrespective of brand)
- Pregnancy and lactation
- Patients with moderate or severe acute illnesses

## Recommendation

- HPV vaccine is safe to use and all available safety data of HPV vaccines do not suggest any safety concern. (Level A)

## EFFICACY OF HPV VACCINE

Prior to licensing, quadrivalent vaccine was evaluated in 2 large Phase-III trials (in addition to a previous Phase-II study) which are named as FUTURE-I<sup>13</sup> and FUTURE-II.<sup>14</sup> These studies involved more than 150 sites in 16 countries and involved more than 17,000 participants.

In Future 1 trial 5455 women between 16 to 24 years were enrolled, and the efficacy of the qHPV vaccine in terms of protection provided against CIN 2/3 and AIS caused by HPV16 or HPV18 was evaluated over a follow up period of three years. In this trial the females who were naive to HPV16/18 one month after the 3rd dose, the protection against combined endpoint was found to be 100% (95% CI 94-100%).<sup>13</sup>

In Future II Study Group 12,167 women aged 15-26 years were included and the efficacy against CIN 2/3 and AIS caused by HPV16/18 was found to be 98% (95% CI, 86-100%) three years after the first dose.<sup>15</sup>

A combined analysis of two Phase III studies, reported by the Future II study group in 2007

included 17,622 females aged 15-26 years, who at the baseline were found to be infected with one or more oncogenic vaccine-related HPV type. The effectiveness of the quadrivalent vaccine was 100% (95% CI 79-100%) against CIN 2/3 and AIS after 3 doses and three years of observation period in women who were sero-negative at enrollment.<sup>16</sup>

Clinical trials of bivalent HPV vaccine have been conducted in more than 18,000 women worldwide receiving the three dose schedule (at 0, 1 & 6 months). The Patricia trial was conducted in women aged 15-25 years, it was a randomized double blind controlled trial. They were vaccinated with HPV16/18 AS04 adjuvant vaccine at 0, 1 & 6 months. The mean follow up was 34.9 months after the 3rd dose and the efficacy of vaccine was 92.9% against CIN2+ associated with HPV 16/18 in the primary analysis and in the according-to-protocol cohort for efficacy it was 98.1%.<sup>17</sup> Another trial, the Costa Rica vaccine trial was conducted on 7466 healthy females aged 18-25 years and were randomized into HPV arm (HPV16/18 vaccine) and control arm (Hepatitis A vaccine). A median follow up of four + years

showed the vaccine efficacy of 89.8% against HPV 16/18 associated CIN2+, and about 59.9% with oncogenic HPV other than 16/18.<sup>18</sup>

On a 15-month follow up of 1113 women aged 15-25 years vaccinated with bivalent HPV 16/18 vaccine, 90% efficacy was found against HPV16/18-related CIN-2/3 and AIS. The study included women who were HPV DNA negative at baseline for vaccine type and received one dose of the vaccine in a modified intention to treat analysis. Over a period of four-five years follow up in the participants did not showed waning immunity.<sup>19</sup>

In 2014 the USFDA approved 9-valent HPV vaccine (9vHPV). This vaccine targets HPV types 6, 11, 16, and 18, as well as HPV types 31, 33, 45, 52, and 58. These five additional HPV types account for about 15% of cancers (14% for females; 4% for males) and approximately 25% of  $\geq$ CIN2.<sup>82</sup> Dosing, precautions and contraindications for HPV 9 are similar to that of Quadrivalent vaccine.<sup>20</sup> At present 9-valent vaccine is not available in India.

# Target population, Dosage schedule and Duration of protection

## 3

### DURATION OF PROTECTION

Women have the risk of getting HPV infection anytime during their sexual life, therefore the overall effectiveness of a vaccine depends on the duration of the protection period. The studies have shown heterogeneity in the methods used for assessing immunogenicity, histopathological and virological end-points and statistical power issues, so it is difficult to interpret the long term effectiveness of the vaccine. Association of higher antibody levels with longer duration of protection is questionable. Vaccine efficacy depends on its ability in disease prevention for a long period of time. To-date the follow up of bHPV vaccine is 9.4 years and for qHPV vaccine is eight years. The follow up of vaccination upto nine years has shown that vaccine is immunogenic and well tolerated.<sup>21-34</sup>

Centre for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG)<sup>35</sup> recommends routine HPV (bHPV or qHPV) vaccination for girls and boys of 11-12 years. According to the Indian Academy of Paediatrics Committee on Immunisation (IAPCOI) all females should receive HPV vaccine, if affordable, starting from age nine years and catch up vaccination at age 13 through 45 years if not already vaccinated.<sup>36</sup>

The ideal time for vaccination would be before start of sexual activity, as vaccine is most effective before getting exposed to HPV infection.<sup>37</sup> Girls aged less than nine should not receive HPV vaccines. The Geometric Mean Titres (GMTs) induced by both vaccines are two times higher in girls aged 10-15 than older girls aged 16-26.<sup>38-40</sup> Catch-up vaccination is recommended up to 26 years of age for girls if they have not taken the vaccination at target age.

In older age groups(15-26years) the intention-to-treat naive cohort (in women who were HPV DNA negative at baseline, were HPV sero-negative for HPV 6/11/16/18 and had normal cytology) who received at least one dose of the qHPV vaccine, 100% efficacy was seen in preventing HPV-type related CIN 3 disease.<sup>38</sup>

### *Cross-protection against non-vaccine HPV types*

Quadrivalent HPV vaccine provides cross protection to some extent against other hrHPV types apart from HPV 16 & 18. The efficacy of qHPV vaccine against CIN2+ caused by any of the 10 most common oncogenic non-vaccine types was found to be 32.5% (95% CI: 6.0–51.9) in the FUTURE I and FUTURE II studies.<sup>41</sup>

A systematic review and meta analysis included 46 publications, and most of them

had a maximum follow up period of four years. During this follow up a borderline protective effect with a pooled RR of 0.80 (95% CI: 0.62-1.02) was observed in all CIN2+ with catch-up vaccination. There was reduction in VIN2+ and VaIN2+ lesions, and condyloma with catch-up vaccination. The long-term effect of this catch up vaccination in prevention of cervical cancer and its related mortality is still unclear.<sup>42</sup> Another study by Munoz N in 2009 concluded that the qHPV vaccine is effective when given to women aged 24-45 years, not found to be infected with relevant HPV types at enrollment.<sup>43</sup>

## Recommendations

- HPV vaccines are licensed for use in females aged 9-45 years; however the preferred target age group is 9-14 years. (Level A)
- Vaccination in sexually active females may be less effective, but may provide some benefit as exposure to all vaccine types previously is unlikely. (Level B)
- Females aged 15-25 years should be considered for catch-up vaccination program only if resources are available. (Level B)

## Dosage Schedules

HPV vaccines are administered as a two-dose series for those who initiate vaccination at ages 9 through 14 years, and a three-dose series for those who initiate at ages 15 through 26 years, and for immunocompromised persons. The number of recommended doses is based on age at administration of the first dose. The minimum interval of six months is recommended between two dose schedules for girls aged < 15 years. An additional third dose is required at least six months after the first dose if the interval between two doses is less than five month.<sup>20,44</sup> It Though

the maximum interval between the doses is not recommended, but a duration of 12-15 months to complete the vaccination schedule before sexual activity.

A large multicentric cohort study was conducted in 188 clusters (9 locations) in India, in which 17,729 unmarried girls aged 10-18 years were vaccinated with QHPV vaccine. They were divided into four cohorts—those who received three doses at 0, 2 & 6 months, two doses at 0 & six months, two doses at 0 & 2 months by default and those who received one dose by default. It was found that the geometric mean avidity indices were non-inferior when the fewer than three doses by design and default were compared to three doses of vaccine. Those girls who received fewer than three doses by design and default had detectable neutralizing antibody concentration to all the 4 HPV vaccine types but the concentrations were much lower in those who received one dose.<sup>45</sup>

## Recommendations

- Girls aged 9-14 years of age should receive two doses of HPV vaccine at least six months apart, although the interval between two doses can be extended to 12-15 months in circumstances where the second dose is not repeated within six months. (Level A)
- Catch-up vaccination can be offered to females more than 15 years till 26 years. They should receive three doses, however the second dose should be given after one or two months (depending on the vaccine that is used) and third dose after six months of the first dose. (Level A)
- Older girls/women who have been sexually active should be counselled regarding reduced efficacy of HPV vaccine and the importance of screening from the age of 25 years. (Level A)

# Special situations

## *Interrupted Dosage Schedule*

In case the vaccine schedule is interrupted or there is delay in taking second or third dose, the vaccine series need not be restarted.<sup>20,44</sup>

Dose interruption may also occur due to non-compliance with scheduled vaccination or pregnancy. For dose interruption due to pregnancy, please refer to the appropriate section entitled 'Vaccination in pregnancy'.

In a study conducted in Vietnam the three doses of qHPV vaccine given as a standard dosing schedule (0, 2, 6 months) was compared with three alternative dosing schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months).<sup>46</sup> The use of two alternative dosing schedules (at 0, 3, 9 months and at 0, 6, 12 months) was non-inferior in terms of antibody concentrations when compared with a standard dosing schedule. However the group that received doses at 0, 12, 24 months did not meet the non-inferiority criteria.<sup>47</sup> Follow up of the women enrolled in this study did not show inferior immune responses after > 2.5 years of follow up after the third dose.<sup>47</sup>

## **Recommendations**

- A two-dose schedule with a minimum interval of six months between two doses is recommended for girls aged <15 years.

If the time period between two vaccine doses is less than five months, a third dose is recommended six months after the first dose. (Level A)

- There is no recommendation for maximum interval between two doses, but a period not more than 12-15 months is required to complete vaccination schedule. (Level B)
- There is no need to restart the vaccine schedule, when the second or third dose is delayed. (Level A)

## *Co-administration with Other Vaccines*

Bivalent or quadrivalent vaccines can be given with other age specific vaccines, such as diphtheria, acellular pertussis and tetanus, alone or in combination (dTpa, dTpa-IPV vaccines) and also with quadrivalent meningococcal conjugate vaccines. Giving age specific vaccines with a separate syringe at different sites in the same visit increases the chance of receiving vaccine on schedule and will reduce the number of visits to the health care center.<sup>20</sup>

Concomitant use of HPV vaccine with recombinant Hepatitis B vaccine is found to be safe in girls and women aged 16 to 23 years. The adverse reactions were similar in concomitant vaccination when compared to Gardasil or

recombinant Hepatitis B alone<sup>48,49</sup> There is no clinically relevant interference reported with antibody response to any of the components of these vaccines.

Immunogenicity and safety is proven for co-administration with combined Hepatitis A and B vaccine.<sup>50</sup> Studies have shown that the vaccines are generally well tolerated, and the immune responses were non-inferior when used in combination compared with non-concomitant administration.<sup>51-53</sup> The immunogenicity of dTpa-IPV and the first dose of HPV vaccine was found to be similar.

## Recommendation

- HPV vaccine can be safely administered with other age appropriate vaccines. (Level A)

## Victims of Sexual Abuse

The risk of HPV infection increases with sexual abuse and assault and is attributable to abuse itself, increased risk for future victimization, and subsequent engagement in at-risk behavior. Though, vaccination does not provide any benefit in terms of viral clearance or protection against disease progression in an already acquired infection, but it provides protection against the infection which are not yet acquired. Children who undergo sexual abuse have more chances of engaging in unsafe sexual practices at an earlier age. Health care workers should be aware of the need for HPV vaccination in females with a history of sexual abuse or assault.<sup>54</sup>

Advisory Committee on Immunization Practices (ACIP) and Centre for Disease Control (CDC) recommends HPV vaccination for both male and female sexual assault survivors aged 9-21 years and 9-26 years, respectively. In case of sexual assault the three dose schedule is followed with the first dose being given at time of initial examination and follow up doses, in the first or 2<sup>nd</sup> month and the second in the 6<sup>th</sup>

month after the first dose. American Academy of Paediatrics (AAP) also recommends HPV vaccination beginning at nine years of age in sexually abused females. There are not enough studies to prove the efficacy of HPV vaccines in sexually abused or assaulted women.

## Recommendation

- Sexual assault survivors should be given a three dose course of HPV vaccine, with the first dose being given at the time of initial examination. (Level B)

## Administration in Older Age Groups

The vaccine is most effective in sexually naive girls and young female i.e, before they are exposed to HPV infection. The new infections usually do not progress to CIN 2 or worse and are associated with a low risk of developing cervical cancer in older women. So vaccine prophylaxis in order to prevent infections with high-risk HPV types leading to cancer at older ages is questionable.<sup>55-57</sup>

Although HPV incidence decreases with age, women more than 25 years remain at risk of developing new HPV infections.<sup>43,58</sup> In the study by Castellsague X *et al* which evaluated the efficacy of Quadrivalent vaccine in women aged 24-45, it was found that the efficacy of the vaccine against the combined incidence of persistent infection, CIN or extra genital lesion related to HPV6/11/16/18 in the per-protocol efficacy (PPE) population was 88.7% (95% CI: 78.1, 94.8), and the efficacy in seropositive and DNA negative women for HPV6/11/16/18 vaccine type at the time of enrollment was 66.9% (95% CI: 4.3, 90.6). Due to limitations of the study, the efficacy against CIN 2/3 was not statistically significant in women aged 24-45 years.<sup>59</sup> Antibody levels are also found to be lower in older age group but remain substantially higher than those induced by natural infection for at least six years following the first dose. To conclude the utility of Quadrivalent HPV vaccine in adult women is still not adequately known but there

could be small benefit on individual basis by vaccinating adult women. In United States for women older than 26 years HPV vaccines are not licensed currently.<sup>60</sup>

However, strong HPV-16 and 18-specific anti-body response was reported in women up to 55 years in a study, but there was a decrease in the antibody titers which was age-dependent. Antibody titers in 46- 55yrs age group was eight-fold higher than titers due to natural infection in 15-25 year age group. Evidence for efficacy in age > 45 years are lacking.<sup>61</sup>

## Recommendations

- For women aged 25 to 45, the first priority should be given to cervical cancer screening. Cervical cancer screening and HPV vaccination are not mutually exclusive. (Level A)
- When women aged 25-45 years are vaccinated, they should be counselled about the reduced efficacy of the vaccine. (Level A)

## ***Women with abnormal Pap smear or positive HPV test or Previous HPV Lesions***

Women with cervical screening abnormalities may have been associated is the one or more types of HPV infection. As the abnormality in Pap's increases, the chance of infection with HPV 16 or 18 increases with a decrease in the expected benefit of the vaccine.

Although these women can be vaccinated still, but with prior proper counseling that vaccine will not help in treating the already existing HPV infection, HPV associated Precancerous lesion, cancer or anogenital warts.<sup>62</sup>

## Recommendation

- Women with abnormal Pap/HPV screening results or previous HPV lesions can be vaccinated if they desire, however they should be counseled about the lack of any therapeutic effects on the existing pathology and reduced efficacy of the vaccine in older women. (Level B)



# Special populations

## *Vaccination–Pregnancy and lactation*

HPV vaccination should not be initiated during pregnancy, but if a woman becomes pregnant after starting the vaccination schedule, termination is not required and the remaining dose(s) should be given after delivery without repeating the initial dose(s).

If a vaccine dose is given during pregnancy, no intervention is needed and lactation is not a contraindication for HPV vaccination.

The data available from various studies did not show any increase in the risk of adverse effects either in mother or baby due to HPV vaccination given in the lactation period.<sup>20,63</sup> Although clinical trials that led to licensure of both the vaccines excluded pregnant women, and the study participants had to avoid conception within two months of the last dose. However, among HPV vaccine recipients (who participated in clinical trials of both vaccines), more than 6500 pregnancies have occurred.<sup>64</sup> There was no significant differences observed in the rates of any specific pregnancy outcomes between the vaccine and the placebo recipients. The manufacturers of both vaccine companies maintained a registry of the women who were inadvertently vaccinated during pregnancy and they did not find any increase in the rate of major congenital malformation and spontaneous abortions.<sup>63</sup>

## Recommendation

- HPV vaccine should not be initiated during pregnancy. (Level A) However if pregnancy is detected after initiation of the vaccine it is advisable to discontinue the schedule and continue the vaccine six weeks post delivery pregnancy. (Level A)

## *Immunocompromised Women*

### HIV infection

HPV and HIV infection share a common route of transmission, and therefore, the vulnerable populations often coincide. In HIV-positive women HPV infection is significantly more common as compared to HIV-negative women across all age groups. HPV infection increases with age in HIV positive women.<sup>65</sup> HPV Vaccine was well tolerated in HIV-infected children aged 7-12 years and was found to be safe and immunogenic. The occurrence of adverse events was similar in qHPV and placebo recipients and were infrequent, except for a more frequent injection site reactions in Quadrivalent HPV recipients.<sup>66</sup> Quadrivalent vaccine was found to be both safe and highly immunogenic in HIV-1 infected men and women with  $\geq 95\%$  seroconversion for each of the HPV types.<sup>67</sup>

## Recommendation

- HIV-positive girls should be advised to start HPV vaccination from 9-14 years and should be prescribed three dose schedule (0, 1, 6 months) (Level B)

### *Vaccination of Males*

The quadrivalent HPV vaccine for boys and young men was licensed by the US Advisory Committee in Immunization Practices (ACIP) in 2009, three years after licensing qHPV for girls.<sup>68</sup> It is upto 90% effective in young men in prevention of HPV infection which includes genital warts and anal epithelial neoplasia.<sup>69,70</sup> It also provides protection against high-risk HPV(HPV16&18), which are associated with various other cancers.<sup>71</sup>

Quadrivalent vaccine is recommended for boys aged 11-21 years, and has been approved up to age 26, for prevention of genital warts and anal cancer.<sup>72</sup> In MSM (Men Who Have Sex with Men) also, it is approved upto the age of 26.<sup>72</sup> Quadrivalent Vaccination programs will help in reducing the burden of HPV-related diseases and cancers.<sup>73-76</sup>

There has been a significant increase in the vaccination coverage among boys in USA, in 2013, approximately 34.6% of boys received one dose of qHPV vaccine in age group 13-17 years.<sup>74</sup> Though there has been an increase in

the vaccination coverage, only 13.9% of boys completed the recommended three-dose of vaccines.<sup>77</sup>

Australia first initiated a government-funded universal HPV vaccination for school boys in February 2013.<sup>78</sup> Routine qHPV vaccination is recommended for both boys and girls by US ACIP, for the children aged 9-18 years who are uninsured or under-insured and the HPV vaccination is financed by the Vaccines for Children (VFC) Program.<sup>72,79</sup> Those who were not eligible for VFC vaccination were electively covered by State.<sup>80</sup>

In 2008 National Immunization Program was started in UK which provided universal coverage for girls only,<sup>81</sup> similar to most of the European countries.<sup>82,83</sup> In 2014 Austria was the first to initiate a gender neutral HPV vaccination program.<sup>84</sup> In Canada 11 provinces and territories immunized only girls in HPV vaccination program.

In countries where vaccination in males is introduced they had already achieved optimal vaccination coverage in girls. Vaccination in girls still remain the priority and vaccination in males in developing countries and in resource-limited countries are not in practice.

## Recommendation

- Vaccination in males is not recommended at present in the Indian setting. (Level C)

# References



1. Rodriguez A.C, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME *et al.* Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. *J Natl Cancer Inst.* 2010; 102 (5):315-24.
2. Kaarthigeyan. Cervical cancer in India and HPV vaccination. *Indian J Med Paediatr Oncol.* 2012 ;33(1): 7–12.
3. Carter J.J, Koutsky L.A, Hughes J.P, *et al.* Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. *J Infect Dis* 2000; 181: 1911–9.
4. Munoz N, Bosch, F. X., De Sanjose, S, Herrero, R, Castellsague, X, Shah, K.V *et al.* “Epidemiologic classification of human papillomavirus types associated with cervical cancer”. *N Engl J Med.* 2003; 348 (6): 518–27.
5. Bhatla N, Lal N, Bao Y-P, *et al.* A meta analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. *Vaccine* 2008; 26: 2811–7.
6. Sankaranarayanan R, Bhatla N, Basu P. Current global status & impact of human papillomavirus vaccination: Implications for India. *Indian J Med Res.*2016; 144: 169-80.
7. Myers E.R, Mc Crory D.C, Nanda K, Bastian L, Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. *Am J Epidemiol.* 2000; 151: 1158-1171.
8. Winer R.L, Hughes J.P, Feng Q, O’Reilly S, Kiviat N.B, Holmes KK *et al.* Condom use and the risk of genital human papillomavirus infection in young women. *N Engl J Med* 2006; 354(25):2645–54.
9. Singhal T. Indian Academy of Pediatrics Committee on Immunisation (IAPCOI) -Consensus Recommendation on Immunization 2008. *Indian Pediatr.* 2008; 45: 635–48.
10. Sankaranarayanan R, Prabhu P.R, Pawlita M, Gheit T, Bhatla N, Muwonge R *et al.* Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. *The Lancet Oncol* 2016; 17(1)66-77.
11. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: A systematic

- review of randomized controlled trials. *CMAJ*. 2007; 177: 469–79.
12. Global Advisory Committee on Vaccine Safety. Brief report on the June 2016 meeting; Update on HPV vaccine safety, October 2017.
  13. Garland S.M, Hernandez-Avila M, Wheeler C.M, Perez G, Harper D.M, Leodolter S *et al*. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med* 2007; 356(19):1928-43.
  14. Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. *N Engl J Med* 2007;356:1915–27.
  15. The FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. *N Engl J Med* 2007; 356(19):1915-27.
  16. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent Human Papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. *J Infect Dis* 2007; 196(10):1438-46.
  17. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D *et al*. for the HPV PATRICIA Study Group. Efficacy of Human Papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 2009; 374: 301–14.
  18. Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubinc G, Herrero R for the CVT Group. Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. *Vaccine* 2014;32(39): 5087-97.
  19. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A *et al*. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet*. 2004; 364(9447):1757-65.
  20. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J *et al*. *MMWR Recommendation and Reports* 2014; 63(RR05):1-30.
  21. Toh ZQ, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu T *et al*. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. *Clin Infect Dis*. 2017; 64(7):852-59
  22. De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. Long-term efficacy and safety of human papillomavirus vaccination. *Int J Womens Health*. 2014; 6: 999-1010.
  23. Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM *et al*. HPV-010 Study Group. Comparison of long-term immunogenicity and safety of Human Papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. *Hum Vaccin Immunother*. 2014; 10(12):3435-45.
  24. Delere Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F *et al*. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta analysis. *Dtsch Arztebl Int*. 2014; 111(35-36):584-91.
  25. Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS *et al*. Long-term study of a quadrivalent

- human papillomavirus vaccine. *Pediatrics*. 2014;134(3):e657-65.
26. Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M *et al*. The clinical effectiveness and cost effectiveness of primary human papillomavirus cervical screening in England: extended follow up of the ARTISTIC randomised trial cohort through three screening rounds. *Health Technol Assess*. 2014;18 (23):1-196.
  27. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T *et al*. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow up. *Hum Vaccin Immunother*. 2012; 8(3):390-7.
  28. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. *Hum Vaccin*. 2011;7(2):161-9.
  29. Villa LL, Ault KA, Giuliano AR, *et al*. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. *Vaccine*. 2006; 24(27– 28):5571–5583.
  30. Luna J, Plata M, Gonzalez M, *et al*. Long-term follow up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. *PLoS One*. 2013; 8(12):e83431.
  31. Giuliano A.R, Palefsky J.M, Goldstone S, *et al*. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med*. 2011; 364(5): 401–411.
  32. Palefsky J.M, Giuliano A.R, Goldstone S, *et al*. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*. 2011; 365(17):1576–1585
  33. Naud P.S, Roteli-Martins C.M, De Carvalho N.S, *et al*. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow up study up to 9.4 years post-vaccination. *Hum Vaccin Immunother*. 2014; 10(8): 2147-62.
  34. Schwarz TF, Spaczynski M, Schneider A, *et al*. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years. *Hum Vaccin*. 2011; 7(9):958–65.
  35. Committee Opinion No. 641: Human Papillomavirus Vaccination. *Obstet Gynecol* 2015;126:e38–43.
  36. Indian Academy of Pediatrics (IAP) Recommended Immunization Schedule for Children Aged 0 through 18 years – India, 2014 and Updates on Immunization *Indian Pediatrics* 2014; 51: 785-800.
  37. HPV and HPV Vaccine - HCP. <http://www.cdc.gov/std/HPV/STDFact-HPV-vaccine-hcp.htm> (accessed 6 Sep2015).
  38. Munoz N, Kjaer S.K, Sigurdsson K, *et al*. Impact of Human Papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst* 2010;102:325–39.
  39. Block SL, Nolan T, Sattler C, *et al*. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. *Pediatrics* 2006;118:2135–45.
  40. Pedersen C, Petaja T, Strauss G, *et al*. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. *J Adolesc Health* 2007;40:564–71.
  41. Brown D.R, Kjaer S.K, Sigurdsson K, *et al*. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16,

- and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. *J Infect Dis* 2009;199:926–35.
42. Couto E, Saeterdal I, Kristine Juvet L, Klemp M. HPV catch-up vaccination of young women: a systematic review and meta analysis. *BMC Public Health* 2014; 14: 867.
  43. Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonogo J, Ault K *et al.* Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. *Lancet*.2009; 373 (9679):1949-57.
  44. Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination-Updated Recommendation of the Advisory Committee on Immunization Practices. *MMWR* 2016; 65(49): 1405-08.
  45. Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R *et al.* Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. *Lancet Oncol* 2016; 17: 67–77.
  46. Neuzil K.M, Canh D.G, Thiem V.D, *et al.* Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. *JAMA* 2011;305: 1424–31.
  47. Lamontagne D.S, Thiem V.D, Huong V.M, *et al.* Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. *J Infect Dis* 2013;208: 1325–34.
  48. Wheeler C.M, Bautista OM, Tomassini J.E, Nelson M, Sattler C.A, Barr E. Safety and immunogenicity of co-administered quadrivalent Human Papillomavirus (HPV)-6/11/16/18 L1 Virus-Like Particle (VLP) and hepatitis B (HBV) vaccines. *Vaccine*. 2008; 26 (5):686-96.
  49. Schmeink C.E, Bekkers R.L, Josefsson A, Richardus J.H, Berndtsson Blom K, David M.P, *et al.* Coadministration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. *Vaccine* 2011; 29 (49):9276–83.
  50. Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlán G, Silfverdal S.A *et al.* Randomized trial: immunogenicity and safety of co-administered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. *J Adolesc Health*. 2012; 50(1):38-46.
  51. Kosalaraksa P, Mehlsen J, Vesikeri T, Meulen A. *Set al.* “An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11–15 Years of Age.” *Pediatr Infect Dis J* 2015; 34 (6): 627-34.
  52. Garcia S.J, Schwarz T.F, Carmona A, Peters K, Malkin J.E, Tran P. *Meta.* “Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine co-administered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women.” *J Adolesc Health* 2010; 46(2): 142-51.
  53. Pandhi D and Sonthalia S. “Human papilloma virus vaccines: Current scenario.” *Indian J Sex Transm Dis*. 2011; 32(2): 75-85.

54. Kaufman M. Committee on Adolescence. Care of the Adolescent Sexual Assault Victim. *Pediatrics* 2008; 122 (2): 462-70.
55. Herrero R, Wacholder S, Rodríguez AC, *et al.* Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. *Cancer Discov* 2011;1: 408–19.
56. Chen H-C, Schiffman M, Lin C-Y, *et al.* Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. *J Natl Cancer Inst* 2011;103:1387–96.
57. Rodríguez A.C, Schiffman M, Herrero R, *et al.* Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. *J Natl Cancer Inst* 2010;102:315–24.
58. Castellsague X, Schneider A, Kaufmann A.M, *et al.* HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. *Gynecol Oncol* 2009;115:S15–23. 17.
59. Castellsague X, Munoz N, Pitisuttithum P, *et al.* End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. *Br J Cancer* 2011; 105:28–37.
60. Human Papillomavirus Vaccination - ACOG. <http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Human-Papillomavirus-Vaccination#16> (accessed 13 Sep2017).
61. Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Gałaj A, Schulze K *et al.* Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label five-year follow up study. *BJOG*. 2015; 122(1): 107–18.
62. Guan P, Clifford GM, Franceschi S. Human papillomavirus types in glandular lesions of the cervix: a meta analysis of published studies. *Int. J. Cancer*, 2013; 132: 248-50.
63. Angelo MG, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. *Pharmacoepidemiol Drug Saf.* 2014;23 (5):456-65.
64. Human papillomavirus vaccines: WHO position paper, October 2014 - Recommendation. *Vaccine* 2014;33:4383–4.
68. Sarkar K, Pal R, Bal B, Saha B, Bhattacharya S, Sengupta S *et al.* Oncogenic HPV among HIV-infected female population in West Bengal, India. *BMC Infect Dis.* 2011; 11: 72.
66. Levin M.J, Moscicki A.B, Song L.Y, Fenton T, Meyer W.A, Read J.S *et al.* Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. *J Acquir Immune Defic Syndr.* 2010; 55 (2):197-204.
67. Wilkin T, Lee J.Y, Lensing S.Y, Stier E.A, Goldstone S.E, Berry J.M *et al.* Safety and immunogenicity of the Quadrivalent human papillomavirus vaccine in HIV-1-infected men. *J Infect Dis.* 2010; 202 (8):1246-53.
68. Centres for Disease Control and Prevention. 2012 Sexually transmitted diseases surveillance 2012. [www.cdc.gov/std/stats12/other.htm#hpv](http://www.cdc.gov/std/stats12/other.htm#hpv).
69. Giuliano A.R, Palefsky J.M, Goldstone S *et al.* Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males. *N. Engl. J. Med.* 2011; 364(5): 401–11.

70. Palefsky J.M, Giuliano A.R, Goldstone S *et al.* HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N. Engl. J. Med.* 2011; 365(17): 1576–85.
71. Dunne E.F, Nielson C.M, Stone K.M, Markowitz L.E, Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. *J. Infect. Dis.* 2006; 194(8):1044–57.
72. Centres for Disease Control and Prevention. Recommendation on the use of quadrivalent human papillomavirus vaccine in males – Advisory Committee on Immunization Practices (ACIP) 2011. [www.cdc.gov](http://www.cdc.gov)
73. Beachler D.C, Weber K.M, Margolick J.B *et al.* Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV negative adults. *Cancer Epidemiol. Biomarkers Prev.* 2012; 21(1):122–33.
74. Mooij S.H, Boot H.J, Speksnijder A *et al.* Oral human papillomavirus infection in HIV-negative and HIV-infected MSM. *AIDS* 2013; 27(13):2117–28.
75. Van Aar F, Mooij S.H, Van der Sande M.A.B *et al.* Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. *AIDS* 2013;27(18): 2921–31.
76. Colon-Lopez V, Ortiz AP, Del Toro-Mejias L, Clatts MC, Palefsky JM. Epidemiology of anal HPV infection in high-risk men attending a sexually transmitted infection clinic in Puerto Rico. *PLoS ONE* 2014; 9(1): e83209.
77. Stokley S, Jeyarajah J, Yankey D *et al.* Human papillomavirus vaccination coverage among adolescents, 2007–2013, and post licensure vaccine safety monitoring, 2006–2014 - United States. *MMWR Morb. Mortal. Wkly. Rep.* 2014; 63(29): 620–24.
78. Australia Government Department of Health. Human papillomavirus. Immunise Australia Program 2014 (2014). <http://www.immunise.health.gov.au>
79. National Center for Immunization and Respiratory Diseases. VFC program: vaccines for uninsured children (2014). [www.cdc.gov/features/vfcprogram](http://www.cdc.gov/features/vfcprogram)
80. The Henry J. Kaiser Family Foundation. The HPV vaccine: access and use in the U.S. Kaiser Family (2014). <http://www.kff.org>
81. Beer H, Hibbits S, Brophy S, Rahman M.A, Waller J, Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK? *Vaccine* 2014; 32(16):1828–33.
82. Burger E.A, SyS, Nygard M, Kristiansen I.S, Kim J.J. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. *PLoS ONE* 2014; 9(3): e89974.
83. European Centre of Disease Prevention and Control. Introduction to HPV vaccines in European Union countries – an update. ECDC, Stockholm (2012). <http://www.ecdc.europa.eu>
84. Smith MA, Canfell K. Incremental benefits of male HPV vaccination: accounting for inequality in population uptake. *PLoS ONE.* 2014; 9(8): e101048.



## **ABOUT PSI**

PSI India is a non-profit, non-governmental organisation enabling people of India to lead healthier lives and plan the families they desire by marketing affordable products and services. We assist and complement the efforts of the Government of India (GoI) in the priority areas – Family Planning, Non Communicable Diseases including Cervical Cancer Prevention, Maternal and Child Health, Sanitation and Gender-based Violence. We use social marketing models and enable quality products and services to reach people at a price they can afford. We apply commercial strategies to the non-profit health sector, allowing women to access care in a place that is convenient, and in a way, they can understand. We are one of the largest organisations in India with many human assets working in several States and Union Territories across India. We believe in creating healthy communities and working conditions.





FOGSI GYNAECOLOGIC ONCOLOGY COMMITTEE  
The Federation of Obstetric & Gynecological Societies of India  
C-5,6,7,12,13, 1st Floor, Trade World, D-wing Entrance,  
S. B. Marg, Kamala City, Lower Parel (W), Mumbai-400013.